10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________________

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to ________

Commission file number 000-56327

NewLake Capital Partners, Inc.

(Exact name of registrant as specified in its charter)

Maryland	83-4400045
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
50 Locust Avenue, First Floor, New Canaan CT 06840	203-594-1402
(Address of principal executive offices)	(Registrants Telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Securities registered pursuant to section 12(g) of the Act:

Common Stock, par value $0.01 per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                                Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                                         Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o	Non-accelerated filer x	Smaller reporting company x
Emerging Growth Company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        Yes o No x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).            Yes o No x

The number of shares of the registrant’s Common Stock, par value $0.01 per share, outstanding as of May 9, 2023 was 21,358,887.

NewLake Capital Partners, Inc.

FORM 10-Q

March 31, 2023

TABLE OF CONTENTS

		Page No.
Part I Financial Information:
Item 1.	Financial Statements (Unaudited)
	Consolidated Balance Sheets	1
	Consolidated Statements of Operations	2
	Consolidated Statements of Equity	3
	Consolidated Statements of Cash Flows	4
	Notes to the Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
	Special Note Regarding Forward Looking Information
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4.	Controls and Procedures	32
Part II Other Information:
Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	34
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 3.	Defaults Upon Senior Securities	34
Item 4.	Mine Safety Disclosures	34
Item 5.	Other Information	34
Item 6.	Exhibits	35
Signatures		36

i

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

NEWLAKE CAPITAL PARTNERS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

	March 31, 2023		December 31, 2022
Assets:	(Unaudited)		(Audited)
Real Estate
Land	$	21,397	$	21,427
Building and Improvements	377,880		378,047
Total Real Estate	399,277		399,474
Less Accumulated Depreciation	(22,796)		(19,736)
Net Real Estate	376,481		379,738
Cash and Cash Equivalents	41,498		45,192
In-Place Lease Intangible Assets, net	21,268		21,765
Loan Receivable	5,000		5,000
Property Held for Sale	1,949		—
Other Assets	2,260		2,554
Total Assets	$	448,456	$	454,249
Liabilities and Equity:
Liabilities:
Accounts Payable and Accrued Expenses	$	1,274	$	1,659
Revolving Credit Facility	1,000		1,000
Loan Payable, net	990		1,986
Dividends and Distributions Payable	8,483		8,512
Security Deposits	7,469		7,774
Rent Received in Advance	651		1,375
Other Liabilities	478		1,005
Total Liabilities	20,345		23,311
Commitments and Contingencies
Equity:
Preferred Stock, $0.01 Par Value, 100,000,000 Shares Authorized, 0 and 0 Shares Issued and Outstanding, Respectively	—		—
Common Stock, $0.01 Par Value, 400,000,000 Shares Authorized, 21,358,887 and 21,408,194 Shares Issued and Outstanding, Respectively	214		214
Additional Paid-In Capital	455,470		455,822
Accumulated Deficit	(34,956)		(32,487)
Total Stockholders' Equity	420,728		423,549
Noncontrolling Interests	7,383		7,389
Total Equity	428,111		430,938
Total Liabilities and Equity	$	448,456	$	454,249

The accompanying notes are an integral part of the consolidated financial statements

1

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share amounts)

	Three Months Ended March 31,
	2023		2022
Revenue:
Rental Income	$	11,157	$	9,097
Interest Income from Loans	128		919
Fees and Reimbursables	131		150
Total Revenue	11,416		10,166
Expenses:
Depreciation and Amortization Expense	3,561		2,679
General and Administrative Expenses:
Compensation Expense	819		836
Stock-Based Compensation	308		405
Professional fees	322		541
Other General and Administrative Expenses	564		532
Total General and Administrative Expenses	2,013		2,314
Total Expenses	5,574		4,993
Loss on Sale of Real Estate	—		(60)
Income From Operations	5,842		5,113
Other Income (Expenses):
Interest Income	220		48
Interest Expense	(92)		(27)
Total Other Income (Expense)	128		21
Net Income	5,970		5,134
Net Income Attributable to Noncontrolling Interests	(102)		(117)
Net Income Attributable to Common Stockholders	$	5,868	$	5,017
Net Income Attributable to Common Stockholders Per Share - Basic	$	0.27	$	0.24
Net Income Attributable to Common Stockholders Per Share - Diluted	$	0.27	$	0.23
Weighted Average Shares of Common Stock Outstanding - Basic	21,423,470		21,382,069
Weighted Average Shares of Common Stock Outstanding - Diluted	21,797,316		21,931,352

The accompanying notes are an integral part of the consolidated financial statements

2

NEWLAKE CAPITAL PARTNERS, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited)

(In thousands, except share amounts)

Three Months Ended March 31, 2023
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Noncontrolling Interest		Total Equity
	Shares	Par
Balance as of December 31, 2022	21,408,194	$	214	$	455,822	$	(32,487)	$	7,389	$	430,938
Repurchase of Common Stock	(49,307)	—		(622)		—		—		(622)
Stock-Based Compensation	—	—		308		—		—		308
Dividends to Common Stock	—	—		—		(8,330)		—		(8,330)
Dividend Equivalents to Restricted Stock Units	—	—		—		(7)		—		(7)
Distributions to OP Unit Holders	—	—		—		—		(146)		(146)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	—	—		(38)		—		38		—
Net Income	—	—		—		5,868		102		5,970
Balance as of March 31, 2023	21,358,887	$	214	$	455,470	$	(34,956)	$	7,383	$	428,111

Three Months Ended March 31, 2022
	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Noncontrolling Interest		Total Equity
	Shares	Par
Balance as of December 31, 2021	21,235,914	$	213	$	450,916	$	(23,574)	$	11,780	$	439,335
Conversion of Vested RSUs to Common Stock	3,002	—		126		—		(126)		—
Conversion of OP Units to Common Stock	61,494	—		1,104		—		(1,104)		—
Stock-Based Compensation	—	—		405		—		—		405
Dividends to Common Stock	—	—		—		(7,029)		—		(7,029)
Dividend Equivalents to Restricted Stock Units	—	—		—		—		(42)		(42)
Distributions to OP Unit Holders	—	—		—		—		(129)		(129)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	—	—		139		—		(139)		—
Net Income	—	—		—		5,017		117		5,134
Balance as of March 31, 2022	21,300,410	$	213	$	452,690	$	(25,586)	$	10,357	$	437,674

The accompanying notes are an integral part of the consolidated financial statements

3

NEWLAKE CAPITAL PARTNERS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	For the Three Months Ended
	March 31. 2023		March 31, 2022
Cash Flows from Operating Activities:
Net Income	$	5,970	$	5,134
Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities:
Stock-Based Compensation	308		405
Loss on Sale of Real Estate	—		60
Depreciation and Amortization Expense	3,557		2,679
Amortization of Debt Issuance Costs	64		—
Amortization of Debt Discount	3		7
Changes in Assets and Liabilities
Other Assets	259		(121)
Accounts Payable and Accrued Expenses	(383)		(685)
Security Deposits	(305)		—
Interest Reserve	—		(919)
Rent Received in Advance	(724)		(323)
Other Liabilities	(512)		—
Net Cash Provided by Operating Activities	8,237		6,237
Cash Flows from Investing Activities:
Escrow Deposits	—		(7,300)
Reimbursements of Tenant Improvements	(1,402)		(3,443)
Acquisition of Real Estate	(350)		—
Disposition of Real Estate	—		761
Net Cash Used in Investing Activities	(1,752)		(9,982)
Cash Flows from Financing Activities:
Repurchase of Common Stock	(622)		—
Common Stock Dividends Paid	(8,349)		(6,593)
Restricted Stock Units Dividend Equivalents Paid	(17)		(42)
Distributions to OP Unit Holders	(146)		(129)
Principal Repayment on Loan Payable	(1,000)		(1,800)
Deferred Financing Costs	(45)		—
Net Cash Used in Financing Activities	(10,179)		(8,564)
Net Increase (Decrease) in Cash and Cash Equivalents	(3,694)		(12,309)
Cash and Cash Equivalents - Beginning of Period	45,192		127,097
Cash and Cash Equivalents - End of Period	$	41,498	$	114,788
Supplemental Disclosure of Cash Flow Information:
Interest Paid	$	94	$	5
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Dividends and Distributions Declared, Not Paid	$	8,483	$	7,200

The accompanying notes are an integral part of the consolidated financial statements

4

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 1 - Organization

NewLake Capital Partners, Inc. (the “Company”), a Maryland corporation, was formed on April 9, 2019, under the Maryland General Corporation Law, as GreenAcreage Real Estate Corp. (“GARE”). The Company is an internally managed Real Estate Investment Trust (“REIT”) focused on providing long-term, single-tenant, triple-net sale-leaseback and build-to-suit transactions for the cannabis industry. The Company’s year-end is December 31. On March 17, 2021, GARE completed a merger (the “Merger”) with another company (the “Target”) that owned a portfolio of cultivation facilities and dispensaries utilized in the cannabis industry, and renamed itself “NewLake Capital Partners, Inc.” The Merger was completed through the issuance of 7,699,887 shares of common stock valued at $21.15 per share and warrants to purchase up to 602,392 shares of the Company’s common stock valued at approximately $4.8 million. Upon completion of the Merger, the Company owned 24 properties across nine states. In connection with the Merger, the Company also entered into various arrangements and agreements with certain of the Company's significant stockholders, including director nomination rights.

The Company conducts its business through its subsidiary, NLCP Operating Partnership LP, a Delaware limited partnership (the “Operating Partnership” or “OP”). The Company holds an equity interest in the Operating Partnership and is the sole general partner. Subsequent to the Merger, the name of the Operating Partnership was changed from GreenAcreage Operating Partnership LP to NLCP Operating Partnership LP.

On August 13, 2021, the Company completed its initial public offering ("IPO") of 3,905,950 shares of common stock, with a par value $0.01 per share. The Company's common stock trades on the OTCQX® Best Market operated by the OTC Markets Group, Inc., under the symbol “NLCP”.

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of the Company, the Operating Partnership, as well as wholly owned subsidiaries of the Operating Partnership’s and variable interest entities ("VIEs") in which the Company is considered the primary beneficiary. The accompanying unaudited financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. In managements opinion, all adjustments (which include only normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the full year or any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and filed with the Securities and Exchange Commission (“SEC”) on March 9, 2023.

Substantially all of the Company's asset are held by and all of its' operations are conducted through the Operating Partnership. The Company is the sole managing general partner of the Operating Partnership. Noncontrolling investors in the Operating Partnership are included in Noncontrolling Interest in the Company's consolidated financial statements. Refer to Note 8 for details. The Operating Partnership is a VIE because the holders of limited partnership interests do not have substantive kick-out rights or participating rights. Furthermore, the Company is the primary beneficiary of the Operating Partnership because it has the obligation to absorb losses and the right to receive benefits from the Operating Partnership and the exclusive power to direct the activities of the Operating Partnership. As of March 31, 2023 and December 31, 2022, the assets and liabilities of

5

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)

the Company and the Operating Partnership are substantially the same, as the Company does not have any significant assets other than its investment in the Operating Partnership.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management will adjust such estimates when facts and circumstances dictate. Such estimates include, but are not limited to, useful lives for depreciation of property, the fair value and impairment of property and in-place lease intangibles acquired, and the fair value of stock-based compensation. Actual results could differ from those estimates.

Reclassification

Certain prior year balances have been reclassified to conform to the Company's current year presentation.

Significant Accounting Policies

There have been no significant changes to the Company's accounting polices included in Note 2 to the Consolidated Financial Statements of the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

Recent Accounting Pronouncements

Description	Adoption Date	Effect on Financial Statements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments — Credit Losses, which among other updates, clarifies that receivables arising from operating leases are not within the scope of this guidance and should be evaluated in accordance with Topic 842.	January 1, 2023	The adoption of this standard did not have a material impact on the Company’s consolidated financial statements due to the limited nature of financial assets held by the Company subject to ASU 2016-13.

6

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 3 - Real Estate

As of March 31, 2023, the Company owned 32 properties, including one that is classified as held for sale, located in 12 states. The following table presents the Company's held for investment real estate portfolio as of March 31, 2023 (dollars in thousands):

Tenant		Market	Site Type	Land		Building and Improvements		Total Real Estate		Accumulated Depreciation		Net Real Estate
Acreage		Connecticut	Dispensary	$	395	$	534	$	929	$	(62)	$	867
Acreage		Massachusetts	Cultivation	481		9,310		9,791		(953)		8,838
Acreage		Pennsylvania	Cultivation	952		9,209		10,161		(910)		9,251
Ayr Wellness, Inc.		Nevada	Cultivation	1,002		12,577		13,579		(297)		13,282
Ayr Wellness, Inc.		Pennsylvania	Cultivation	2,964		11,565		14,529		(314)		14,215
Bloom Medicinal		Missouri	Cultivation	948		11,919		12,867		(232)		12,635
Calypso Enterprises		Pennsylvania	Cultivation	1,486		28,514		30,000		(668)		29,332
Columbia Care		California	Dispensary	1,082		2,692		3,774		(176)		3,598
Columbia Care		Illinois	Dispensary	162		1,053		1,215		(66)		1,149
Columbia Care		Illinois	Cultivation	801		10,560		11,361		(673)		10,688
Columbia Care		Massachusetts	Dispensary	108		2,212		2,320		(156)		2,164
Columbia Care		Massachusetts	Cultivation	1,136		12,690		13,826		(1,079)		12,747
Cresco Labs		Illinois	Cultivation	276		50,456		50,732		(4,643)		46,089
Curaleaf		Connecticut	Dispensary	184		2,748		2,932		(187)		2,745
Curaleaf		Florida	Cultivation	388		75,595		75,983		(4,649)		71,334
Curaleaf		Illinois	Dispensary	69		525		594		(37)		557
Curaleaf		Illinois	Dispensary	65		959		1,024		(70)		954
Curaleaf		Illinois	Dispensary	606		1,128		1,734		(81)		1,653
Curaleaf		Illinois	Dispensary	281		3,072		3,353		(214)		3,139
Curaleaf		North Dakota	Dispensary	779		1,395		2,174		(102)		2,072
Curaleaf		Ohio	Dispensary	574		2,788		3,362		(226)		3,136
Curaleaf		Pennsylvania	Dispensary	877		1,041		1,918		(95)		1,823
Curaleaf		Pennsylvania	Dispensary	216		2,011		2,227		(140)		2,087
Greenlight	(1)	Arkansas	Dispensary	238		1,919		2,157		(134)		2,023
Mint	(2)	Arizona	Cultivation	2,400		11,293		13,693		—		13,693
Organic Remedies		Missouri	Cultivation	204		20,731		20,935		(1,369)		19,566
PharmaCann		Massachusetts	Dispensary	411		1,701		2,112		(209)		1,903
PharmaCann		Ohio	Dispensary	281		1,269		1,550		(15)		1,535
PharmaCann		Pennsylvania	Dispensary	44		1,271		1,315		(81)		1,234
Revolutionary Clinics		Massachusetts	Cultivation	926		41,934		42,860		(2,164)		40,696
Trulieve		Pennsylvania	Cultivation	1,061		43,209		44,270		(2,794)		41,476
Total Real Estate(3)				$	21,397	$	377,880	$	399,277	$	(22,796)	$	376,481

7

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 3 - Real Estate (continued)

(1) GL Partners, Inc. (Greenlight) took over as tenant, however Curaleaf remains the guarantor subject to certain conditions in the lease agreement.

(2) This property is under development. Once completed and placed in service, the Company will start depreciating this property.

(3) The table does not include one property held for sale.

Real Estate Acquisitions

During the three months ended March 31, 2023, the Company invested approximately $350 thousand to acquire one parcel of land and committed to fund $16.2 million to expand a cultivation facility in Missouri . The following table presents the real estate acquisition for the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Closing Date	Real Estate Acquisition Costs
Bloom Medicinal	Missouri	Cultivation	March 3, 2023	$	350	(1)
Total				$	350

(1)The Company exercised its option to purchase the adjacent parcel of land to expand its cultivation facility in Missouri and has committed to fund $16.2 million for the expansion.

During the year ended December 31, 2022, the Company invested approximately $67.0 million to acquire four cultivation facilities and one dispensary. The following table presents the real estate acquisitions for the year ended December 31, 2022 (in thousands):

Tenant	Market	Site Type	Closing Date	Real Estate Acquisition Costs(1)
Bloom Medicinal	Missouri	Cultivation	April 01, 2022	7,301		(2)
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	14,529
Ayr Wellness, Inc.	Nevada	Cultivation	June 30, 2022	13,579
Calypso Enterprises	Pennsylvania	Cultivation	August 05, 2022	30,000		(3)
PharmaCann	Ohio	Dispensary	November 03, 2022	1,550
Total				$	66,959

(1)     Includes the purchase price (and in some cases, transaction costs that have been capitalized into the purchase price) and TI commitments funded at closing, if any, as of December 31, 2022. Excludes TI commitments not funded as of December 31, 2022. Excludes approximately $11.0 thousand of capitalized transaction costs on properties purchased prior to January 1, 2022.

(2)      Includes approximately $5.0 million of TI funded at closing of the property.

(3)     The Company entered into a $30.0 million mortgage loan on October 29, 2021 which converted to a sale-leaseback on August 5, 2022.

Conversion of Mortgage Loan

The Company funded a $30.0 million mortgage loan to Hero Diversified Associates, Inc. (“HDAI" or "Calypso") on October 29, 2021. On August 5, 2022 the mortgage loan converted to a twenty year sale-leaseback and the Company recorded land and building and improvements which have been included in "Total Real Estate" on the consolidated balance sheets.

8

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 3 - Real Estate (continued)

Tenant Improvements Funded

During the three months ended March 31, 2023, the Company funded approximately $1.4 million of tenant improvements. The following table presents the tenant improvements funded for the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Closing Date	TI Funded		Unfunded Commitments
Mint	Arizona	Cultivation	June 24, 2021	$	752	$	802	(1)
Organic Remedies	Missouri	Cultivation	December 20, 2021	116		166
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	534		16,150
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—		750
Total				$	1,402	$	17,868

(1)The tenant has been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.

During the year ended December 31, 2022, the Company funded approximately $45.2 million of tenant improvements. The following table presents the tenant improvements funded for the year ended December 31, 2022 (in thousands):

Tenant	Market	Site Type	Closing Date	TI Funded			Unfunded Commitments
Curaleaf	Florida	Cultivation	August 4, 2020	$	20,983	'(1)	$	—
Mint	Massachusetts	Cultivation	April 1, 2021	349			—
Mint	Arizona	Cultivation	June 24, 2021	7,415			1,554		'(2)
PharmaCann	Massachusetts	Dispensary	March 17, 2021	25			—
Trulieve	Pennsylvania	Cultivation	March 17, 2021	7,046		'(3)	—
Organic Remedies	Missouri	Cultivation	December 20, 2021	4,745			282
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	4,682			534		'(4)
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—			750
Total				$	45,245		$	3,120
(1) On June 16, 2022, the Company funded the expansion of an existing property.
(2) The tenant has been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.
(3) The tenant had been paying rent for the TI since December 2021 in accordance with the lease agreement. As of May 2022, the TI had been fully funded.
(4) The unfunded commitment does not include a $16.5 million option but not obligation to acquire an adjacent property from an existing tenant.

Disposal of Real Estate

There were no sales of real estate during the three months ended March 31, 2023.

On March 21, 2022, the Company sold one of its Massachusetts properties for approximately $0.8 million, which was leased to PharmaCann. The Company recognized a loss on sale of the property of $60 thousand. The Company continued to collect the rent that would have been received from the Massachusetts property through increased lease payments from each of the remaining two properties leased by PharmaCann until the acquisition of a third property that was leased to PharmaCann in November 2022.

9

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 3 - Real Estate (continued)

Real Estate Held for Sale

As of March 31, 2023, the Company is under contract with a broker to sell a property with a carrying amount $1.9 million located in Massachusetts. The property is available for immediate sale in its present condition and management expects the property will sell within one year. A property that is held for sale is required to be recorded at the lower of carrying amount or fair value less cost to sell with a loss recognized if the carrying amount of the property exceeds its fair value less cost to sell. As of March 31, 2023, the property was recorded at its carry value as a result of a make whole provision in the lease agreement.

At March 31, 2023, the property's initial recording amount was $1.9 million and it is classified in "Property Held for Sale" in the accompanying consolidated balance sheet.

Construction in Progress

Construction in progress was $12.9 million and $12.1 million on March 31, 2023 and December 31, 2022, respectively, and is included in "Buildings and Improvements" in the accompanying consolidated balance sheets.

Depreciation and Amortization

Depreciation expense for the three months ended March 31, 2023 and 2022, was $3.1 million and $2.2 million, respectively.

Amortization of the Company’s acquired in-place lease intangible assets was approximately $0.5 million for both the three months ended March 31, 2023 and 2022. The acquired in-place lease intangible assets have a weighted average remaining amortization period of 10.9 years.

In-place Leases

The following table presents the future amortization of the Company’s acquired in-place leases as of March 31, 2023 (in thousands):

Year	Expense
2023 (nine months ending December 31, 2023)	$	1,489
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$	21,268

Impairment

The Company reviewed tenant activities and changes in the business condition of all of its properties and reviewed the existence of potential triggering events or impairment indicators to determine if there is impairment. Based on its review, as of March 31, 2023 and March 31, 2022 no impairment losses were recognized.

10

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 4 - Leases

As Lessor

The Company's properties are leased to single tenants on a long-term, triple-net basis, which obligates the tenant to be responsible for the ongoing expenses of a property, in addition to its rent obligations. The Company's tenants operate in the fast-growing cannabis industry. All of the Company's leases generally contain annual increases in rent (typically between 2% and 3%) over the expiring rental rate at the time of expiration. Certain of the Company's leases also contain a Tenant Improvement Allowance (“TIA”). TIA is generally available to be funded between 12 and 18 months. In some leases, the tenant becomes liable to pay rent as if the full TIA has been funded, even if there are still unfunded commitments. TIA also contains annual increases which generally increase at the same rate as base rent, per the lease agreement. Certain of the Company's leases provide the lessee with a right of first refusal or right of first offer in the event the Company markets the leased property for sale. Two of the Company’s leases that were entered into in December 2020 provide the lessee with a purchase option to purchase the leased property at the end of the initial lease term in December 2029, subject to the satisfaction of certain conditions. The purchase option provision allows the lessee to purchase the leased property for an amount based on the fair market value of the Company's investment. As of March 31, 2023, the Company's gross investment in these two properties was approximately $6.3 million.

The following table presents the future contractual minimum rent under the Company’s operating leases as of March 31, 2023 (in thousands):

Year	Contractual Minimum Rent
2023 (nine months ending December 31, 2023)	$	36,889
2024	51,211
2025	53,405
2026	54,777
2027	56,186
Thereafter	593,151
Total	$	845,619

Concentration of Credit Risk

The ability of any of the Company's tenants to honor the terms of its lease are dependent upon the economic, regulatory, competitive, natural and social factors affecting the community in which that tenant operates.

11

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 4 - Leases (continued)

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's total rental income for each of the periods presented:

For the Three Months Ended March 31,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		11	26%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	'(3)	1	14%
Calypso	1	'(2)	8%	Columbia Care		5	11%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(2) This tenant held a mortgage loan as of the three months ended March 31, 2022, therefore the Company received interest income rather than rental income during that period. In August 2022, the mortgage loan converted to a twenty year sale-leaseback.

(3) This tenant failed to pay rental income during the three months ended March 31, 2023. A security deposit of approximately $315 thousand was applied.

Non-Performing Tenant

Through March 31, 2023, Revolutionary Clinics failed to pay contractual rent, under one lease agreement. The Company is currently in discussion with the tenant to negotiate a resolution, which could include rent deferrals, or other concessions. The Company held a security deposit of approximately three months of contractual rent, of which we applied $315 thousand towards the outstanding rent during the three months ended March 31, 2023.

As Lessee

As of March 31, 2023, the Company was the lessee under one office lease that qualifies under the right-of-use ("ROU") model. The Company recorded a ROU asset of $273 thousand which is classified in “Other Assets” on the Company's consolidated balance sheets through a ROU model, in which the Company recorded a ROU asset and a lease liability. The ROU asset is amortized over the remaining lease term. The amortization is made up of the principal amortization under the lease liability plus or minus the straight-line adjustment of the operating lease rent. The lease liability is included in “Other Liabilities” the Company's consolidated balance sheets.

The following table presents the future contractual rent obligations as lessee as of March 31, 2023 (in thousands):

Year	Contractual Base Rent
2023	$	59
2024	75
2025	77
2026	52
Total Minimum Lease Payments	$	263
Less Amount Discounted Using Incremental Borrowing Rate	48
Total Lease Liability	$	215

12

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 4 - Leases (continued)

As of March 31, 2023, the weighted-average discount rate used to calculate the lease liability was 5.65% and the remaining lease term was 3.4 years.

Note 5 – Loan Receivable

The Company funded a $5.0 million unsecured loan to Bloom Medicinals on June 10, 2022. The loan initially bore interest at a rate of 10.25% and is structured to increase annually in April by the product of 1.0225 times the rate in effect immediately prior to the anniversary date. The loan can be prepaid at any time without penalty and matures on June 30, 2026. The loan is cross defaulted with their lease agreement with the Company. As of March 31, 2023, the aggregate principal amount outstanding on the unsecured loan receivable was $5.0 million.

Note 6 – Financings

Seller Financing

In connection with the purchase and leaseback of a cultivation facility in Chaffee, Missouri on December 20, 2021, the Company entered into a $3.8 million loan payable to the seller, which is an independent third party from the tenant. The loan bears interest at a rate of 4.0% per annum. Principal on the loan is payable in annual installments of which $1.8 million and $1.0 million were paid in January 2022 and January 2023, respectively. The remaining principal of $1.0 million is payable in January 2024. The loan's outstanding balance as of March 31, 2023 was $1.0 million and the remaining unamortized discount was $10.2 thousand.

Revolving Credit Facility

On May 6, 2022, the Company's Operating Partnership entered into a loan and security agreement (the “Loan and Security Agreement”) with a commercial federally regulated bank, as a lender and as agent for lenders that become party thereto from time to time (the “Agent”). The Loan and Security Agreement matures on May 6, 2027. The Loan and Security Agreement provides, subject to the Accordion Feature described below, $30.0 million in aggregate commitments for secured revolving loans (“Revolving Credit Facility”), the availability of which is based on a borrowing base consisting of fee simple owned real properties that satisfy eligibility criteria specified in the Loan and Security Agreement and the lease income thereunder which are owned by certain subsidiaries of the Operating Partnership.

On July 29, 2022, the Operating Partnership, entered into an amendment to the Revolving Credit Facility, amending the Loan and Security Agreement, to increase the aggregate commitment under the Revolving Credit Facility from $30.0 million to $90.0 million and added two additional lenders. The Loan and Security Agreement also allows the Company, subject to certain conditions, to request additional revolving incremental loan commitments such that the Revolving Credit Facility may be increased to a total aggregate principal amount of up to $100.0 million. Borrowings under the Revolving Credit Facility may be voluntarily prepaid and re-borrowed, subject to certain fees.

The Revolving Credit Facility bears a fixed rate of 5.65% for the first three years and thereafter a variable rate based upon the greater of (a) the Prime Rate quoted in the Wall Street Journal (Western Edition) (“Base Rate”) plus an applicable margin of 1.0% or (b) 4.75%.

As of March 31, 2023, the Company had approximately $1.0 million in borrowings under the Revolving Credit Facility and $89.0 million in funds available to be drawn, subject to sufficient collateral in the borrowing base.

13

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 5 – Financings (continued)

The facility is subject to certain liquidity and operating covenants and includes customary representations and warranties, affirmative and negative covenants and events of default. As of March 31, 2023, the Company complied with the terms of such covenants.

Note 7 - Related Party Transactions

Merger Agreement

In connection with the Merger, the Company entered into an Investor Rights Agreement (the "Investor Rights Agreement"). The Investor Rights Agreement provides the stockholders party thereto with certain rights with respect to the nomination of members to the Company's board of directors. Prior to the completion of the Company's IPO, pursuant to the Investor Rights Agreement, HG Vora Capital Management, LLC (“HG Vora”) had the right to nominate four directors to our board of directors. Following the completion of our IPO, for so long as HG Vora owns (i) at least 9% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate two of the members of our board of directors, and (ii) at least 5% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate one member of our board of directors. If HG Vora owns less than 5% of our issued and outstanding common stock for 60 consecutive days, then HG Vora may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Prior to the completion of our IPO, NLCP Holdings, LLC had the right to designate three directors to our board of directors. Subsequent to our IPO, NLCP Holdings, LLC no longer has these rights.

Prior to the completion of our IPO, West Investment Holdings, LLC, West CRT Heavy, LLC, Gary and Mary West 2012 Gift Trust, Gary and Mary West Charitable Trust and WFI Co-Investments acting unanimously, collectively referred to as the “West Stockholders,” did not have a director nomination right. Following the completion of our IPO, the West Stockholders may nominate one member of our board of directors for so long as the West Stockholders own in the aggregate at least 5% of the issued and outstanding shares of our common stock. If the West Stockholders own in the aggregate less than 5% of our issued and outstanding common stock for 60 consecutive days, then the West Stockholders may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Prior to the completion of our IPO, NL Ventures, LLC (“Pangea”) did not have a director nomination right. Following the completion of our IPO, Pangea may nominate one member of our board of directors for so long as Pangea owns at least 4% of our issued and outstanding common stock for 60 consecutive days. If Pangea owns less than 4% of our issued and outstanding common stock for 60 consecutive days, then Pangea may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Note 8 - Noncontrolling Interests

The Company's noncontrolling interests represent limited partnership interest in the Operating Partnership not held by the Company. Noncontrolling interests represented 1.7% and 1.8% ownership in the Operating Partnership at March 31, 2023 and March 31, 2022, respectively.

The following table presents the activity for the Company’s noncontrolling interests issued by the Operating Partnership;

	Three Months Ended March 31, 2023			Three Months Ended March 31, 2022
		OP Units	Noncontrolling Interests %	OP Units	Noncontrolling Interests %
Balance at January 1,		373,582	1.7%	453,303	2.1	%
OP Units Converted		—		(61,494)
Balance at March 31,		373,582	1.7%	391,809	1.8	%

14

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 9 - Stock Based Compensation

The Company's board of directors adopted the 2021 Equity Incentive Plan (the “Plan”), to provide employees of the Company and its subsidiaries, certain consultants and advisors who perform services for the Company or its subsidiaries, and non-employee members of the board of directors of the Company with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards to enable us to motivate, attract and retain the services of directors, officers and employees considered essential to the long term success of the Company. Under the terms of the Plan, the aggregate number of shares of awards will be no more than 2,275,727 shares. If and to the extent shares of awards granted under the Plan, expire or are canceled, forfeited, exchanged or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards are forfeited, terminated or otherwise not paid in full, the shares subject to such grants shall again be available for issuance or transfer under the Plan. The Plan has a term of ten years until August 12, 2031. As of March 31, 2023, there were approximately 1,943,936 shares available for issuance under the Plan.

Restricted Stock Units

During the three months ended March 31, 2023, the Company granted 27,630 RSUs to certain officers and employees of the Company. Total outstanding RSUs as of March 31, 2023 were 75,419. Of the 75,419 outstanding RSUs, 18,534 RSUs were fully vested and 56,885 RSUs were unvested. There were no RSUs that vested or were forfeited during the three months ended March 31, 2023. During the three months ended March 31, 2022, 1,044 RSUs were granted and 4,102 RSUs were forfeited. Total outstanding RSUs as of March 31, 2022 were 169,136. Of the 169,136 outstanding RSUs, 127,176 RSUs were fully vested and 41,960 RSUs were unvested. RSUs are subject to restrictions on transfer and may be subject to a risk of forfeiture if the award recipient ceases to be an employee or director of the Company prior to vesting of the award.

Each RSU represents the right to receive one share of common stock upon vesting. Each RSU is also entitled to receive a dividend equivalent payment equal to the dividend paid on one share of common stock upon vesting. Unearned dividend equivalents on unvested RSUs as of March 31, 2023 and 2022 were $60,760 and $26,854, respectively.

The amortization of compensation costs for the awards of RSUs are included in "Stock-Based Compensation" in the accompanying consolidated statements of operations and amounted to approximately $0.1 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively. The remaining unrecognized compensation cost of approximately $0.7 million for RSU awards is expected to be recognized over a weighted average amortization period of 1.6 years as of March 31, 2023.

The following table sets forth the Company's unvested restricted stock units activity for the three months ended March 31,:

	2023			2022
	Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	29,255	$	22.89	45,018	$	27.49
Granted	27,630	$	13.38	1,044	$	27.49
Forfeited	—	$	—	(4,102)	27.49
Balance at March 31,	56,885	$	18.27	41,960	$	27.49

15

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 9 - Stock Based Compensation (continued)

Performance Stock Units

During the three months ended March 31, 2023, the Company granted 55,017 Performance Stock Units (“PSUs”) to officers and certain employees of the Company. Total outstanding PSUs as of March 31, 2023 and 2022 were 121,858 and 77,742, respectively. During the three months ended March 31, 2023 and 2022, no PSUs vested or were forfeited. PSUs vest subject to the achievement of relative total shareholder return as measured against a peer group of companies and absolute compounded annual growth in stock price during each performance period. The actual number of shares of common stock issued will range from 0 to 243,716 depending upon performance. The performance periods are August 13, 2021 through December 31, 2023, January 1, 2022 through December 31, 2024, and January 1, 2023 through December 31, 2025 and 18,858, 47,983 and 55,017 PSUs are scheduled to vest at the end of each performance period, respectively.

PSUs are recorded at fair value which involved using a Monte Carlo simulation for the future stock prices of the Company and its corresponding peer group. A fair value of $24.15, $24.00 and $11.23 were used for PSUs with performance periods ending December 31, 2023, 2024 and 2025, respectively. PSUs are subject to restrictions on transfer and may be subject to a risk of forfeiture if the award recipient ceases to be an employee of the Company prior to vesting of the award.

Each PSU is entitled to receive a dividend equivalent payment equal to the dividend paid on the number of shares of common stock issued per PSU vesting. Unearned dividend equivalents on unvested PSUs as of March 31, 2023 and 2022 were $164,496 and $49,755, respectively.

The amortization of compensation costs for the awards of PSUs are included in "Stock-Based Compensation" in the accompanying consolidated statements of operations and amounted to $0.2 million for the three months ended March 31, 2023 and 2022. The remaining unrecognized compensation cost of approximately $1.4 million for PSU awards is expected to be recognized over a weighted average amortization period of 2.1 years as of March 31, 2023.

The following table sets forth the Company's unvested performance stock activity for the three months ended March 31,:

	2023			2022
	Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	66,841	$	24.04	77,742	$	24.04
Granted	55,017	$	11.23	—	$	—
Balance at March 31,	121,858	$	18.26	77,742	$	24.04

Stock Options

Prior to the completion of the IPO, the Company issued 791,790 nonqualified stock options (the “Options”) to purchase shares of the Company’s common stock, subject to the terms and conditions of the applicable Option Grant Agreements, with an exercise price per share of common stock equal to $24.00 and in such amounts as set forth in the Option Grant Agreements. The Options vested on August 31, 2020 and were fully exercisable as of March 31, 2023. The options expire on July 15, 2027.

16

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 10 - Warrants

On March 17, 2021, in connection with the Merger, the Company entered into a warrant agreement which granted the right to purchase 602,392 shares of common stock of the Company at a purchase price of $24.00 per share. Warrants are immediately exercisable and expire on July 15, 2027.

The following table summarizes warrant activity for the three months ended March 31,:

	2023			2022
	Number of Warrants	Weighted Average Exercise Price		Number of Warrants(1)	Weighted Average Exercise Price
Exercisable at January 1,	602,392	$	24.00	602,392	$	24.00
Granted	—	—		—	—
Exercised	—	—		—	—
Exercisable at March 31,	602,392	$	24.00	602,392	$	24.00

(1)Warrants granted on March 17, 2021.

Note 11 - Stockholders' Equity

Preferred Stock

As of March 31, 2023, the Company had 100,000,000 shares of preferred stock authorized and 0 shares of preferred stock outstanding.

Common Stock

Stock Repurchase Program

On November 7, 2022, the board of directors of the Company authorized a stock repurchase program of its common stock up to $10.0 million through December 31, 2023. Purchases made pursuant to the stock repurchase program will be made in the open market, in privately negotiated transactions, or pursuant to any trading plan that may be adopted in accordance with Rule 10b-18 of the Securities and Exchange Act of 1934, as amended. The authorization of the stock repurchase program does not obligate the Company to acquire any particular amount of common stock. The timing, manner, price and amount of any repurchases will be determined by the Company in its discretion and will be subject to economic and market conditions, stock price, applicable legal requirements

17

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 11 - Stockholders' Equity (continued)

and other factors. The stock repurchase program may be suspended or discontinued by us at any time and without prior notice.

For the three months ended March 31, 2023, pursuant to the repurchase plan, the Company acquired 49,307 shares of common stock with an average price, including commissions, of $12.63 totaling approximately $622 thousand. The remaining availability under the program as of March 31, 2023 was approximately $9.4 million

Conversion of OP Units

There were no OP Units converted during the three months ended March 31, 2023. During the three months ended March 31, 2022, 61,494 OP Units were converted one for one into our common stock.

Dividends

The following tables describe the cash dividends, dividend equivalents on vested RSUs and, in the Company's capacity as general partner of the operating partnership, authorized distributions on the Company's OP Units declared by the Company during the three months ended March 31, 2023 and 2022:

Declaration Date	Record Date	Period Covered	Distributions Paid Date	Amount per Share/Unit
March 7, 2023	March 31, 2023	January 1, 2023 to March 31, 2023	April 14, 2023	$	0.39
Total				$	0.39

Declaration Date	Record Date	Period Covered	Distributions Paid Date	Amount per Share/Unit
March 15, 2022	March 31, 2022	January 1, 2022 to March 31, 2022	April 14, 2022	$	0.33
Total				$	0.33

During the three months ended March 31, 2023 and 2022, the Company paid $8,685 and $1,436, respectively, of dividend equivalents that became earned upon vesting of RSUs. The Company had accrued unearned dividend equivalents on unvested RSUs and unvested PSUs of $225,256 and $76,609, as of March 31, 2023 and 2022, respectively.

18

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 12 - Earnings Per Share

The following table presents the computation of basic and diluted earnings per share (in thousands, except share data):

	For the Three Months Ended March 31,
	2023		2022
Numerator:
Net Income Attributable to Common Stockholders	$	5,868	$	5,017
Add: Net Income Attributable to Noncontrolling Interest	102		117
Net Income Attributable to Common Stockholders - Diluted	$	5,970	$	5,134
Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic	21,423,470		21,382,069
Dilutive Effect of OP Units	373,582		438,375
Dilutive Effect of Options and Warrants	—		65,099
Dilutive Effect of Unvested Restricted Stock Units	264		45,809
Weighted Average Shares of Common Stock - Diluted	21,797,316		21,931,352
Earnings Per Share - Basic
Net Income Attributable to Common Stockholders	$	0.27	$	0.24
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholders	$	0.27	$	0.23

During the three months ended March 31, 2023, the effect of including unvested restricted stock units and OP units were included in the Company's calculation of weighted average shares of common stock outstanding – diluted. The effect of outstanding stock options and outstanding warrants were excluded in the Company's calculation of weighted average shares of common stock outstanding – diluted as their inclusion would have been anti-dilutive. During the three months ended March 31, 2022, the effect of including OP Units, outstanding stock options, outstanding warrants and unvested restricted stock units were included in the Company's calculation of weighted average shares of common stock outstanding – diluted.

Note 13 – Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standards describe three levels of inputs that may be used to measure fair value:

Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 – Includes other inputs that are directly or indirectly observable in the marketplace.

19

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

(Unaudited)

Note 13 – Fair Value Measurements (continued)

Level 3 – Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.

The following table presents the carrying value and estimated fair value of financial instruments at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023				December 31, 2022
	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Note Receivable(1)	$	5,000	$	4,907	$	5,000	$	4,952
Revolving Credit Facility(2)	$	1,000	$	905	$	1,000	$	915
Seller Financing(2)	$	990	$	959	$	1,986	$	1,942

(1) The fair value measurement of the $5.0 million Note Receivable is based on unobservable inputs, and as such, is classified as Level III.

(2) This fair value measurement of the Company’s Revolving Credit Facility and Seller Financing is based on observable inputs, and as such, are classified as Level II.

As of March 31, 2023 and December 31, 2022, the carrying amounts of financial instruments such as cash and cash equivalents, accounts payable and accrued expenses and other liabilities approximate their fair values due to their generally short-term nature and the market rates of interest of these instruments.

Note 14 - Commitments and Contingencies

As of March 31, 2023, the Company had aggregate unfunded commitments to invest $17.9 million to develop and improve its' existing cultivation facilities in Arizona, Missouri, and Pennsylvania. Refer to Note 3 for further details on the Company's commitments.

The Company owns a portfolio of properties that it leases to entities which cultivate, harvest, process and distribute cannabis. Cannabis is an illegal substance under the Controlled Substances Act. Although the operations of the Company’s tenants are legalized in the states and local jurisdictions in which they operate, the Company and its tenants are subject to certain risks and uncertainties associated with conducting operations subject to conflicting federal, state and local laws in an industry with a complex regulatory environment which is continuously evolving. These risks and uncertainties include the risk that the strict enforcement of federal laws regarding cannabis would likely result in the Company’s inability, and the inability of its tenants, to execute their respective business plans.

Note 15 - Subsequent Events

Tenant Improvements

Subsequent to March 31, 2023, the Company funded approximately $0.8 million of tenant improvements to our cultivation facility located in Arizona.

20

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

SPECIAL NOTE REGARDING FORWARD LOOKING INFORMATION

NewLake Capital Partners, Inc. ("the Company," "we," "our," "us,") makes statements in this Quarterly Report on Form 10-Q (“Form 10-Q”) that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, statements pertaining to our capital resources, property performance, leasing rental rates, future dividends and results of operations contain forward-looking statements. Likewise, all of our statements regarding anticipated growth in our funds from operations, adjusted funds from operations, anticipated market conditions, demographics, and results of operations are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believe,” “continue,” “could,” “expect,” “may,” “will,” “should,” “would,” “seek,” “approximately,” “intend,” “plan,” “pro forma,” “estimates,” “forecast,” “project,” or “anticipate” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

•actions and initiatives of the U.S. or state governments and changes to government policies and the execution and impact of these actions, initiatives and policies, including the fact that cannabis remains illegal under federal law;

•general economic conditions;

•adverse economic or real estate developments, either nationally or in the markets in which our properties are located;

•other factors affecting the real estate industry generally;

•increase in interest rates and operating costs;

•the impact of inflation;

•financial market fluctuations;

•the competitive environment in which we operate;

•the estimated growth in and evolving market dynamics of the regulated cannabis market;

•adverse economic effects on the cannabis market;

•the expected medical-use or adult-use cannabis legalization in certain states;

•shifts in public opinion regarding regulated cannabis;

•the additional risks that may be associated with certain of our tenants cultivating adult-use cannabis in our cultivation facilities;

•the risks associated with the development of cultivation centers and dispensaries;

•our ability to successfully identify opportunities in target markets;

•the lack of tenant security deposits will impact our ability to recover rents should our tenants default under their respective lease agreement;

21

Table of Contents

•our status as an emerging growth company and a smaller reporting company;

•our lack of an extensive operating history;

•the concentration of our tenants in certain geographical areas;

•our failure to generate sufficient cash flows to service any outstanding indebtedness;

•defaults on, early terminations of or non-renewal of leases by tenants, including significant tenants;

•our failure to acquire the properties in our identified pipeline successfully, on the anticipated timeline or at the anticipated costs;

•our failure to properly assess employment growth or other trends in target markets and other markets in which we seek to invest;

•lack or insufficient amounts of insurance;

•bankruptcy or insolvency of a significant tenant or a substantial number of smaller tenants;

•our access to certain financial resources, including banks and other financial institutions;

•reduced liquidity of our common stock resulting from limited availability of clearing firms that will settle our

securities offerings;

•our failure to successfully operate acquired properties;

•our ability to operate successfully as a public company;

•our dependence on key personnel and ability to identify, hire and retain qualified personnel in the future;

•conflicts of interests with our officers and/or directors stemming from their fiduciary duties to other entities, including our operating partnership;

•our failure to obtain necessary outside financing on favorable terms or at all;

•general volatility of the market price of our common stock;

•changes in GAAP;

•environmental uncertainties and risks related to adverse weather conditions and natural disasters;

•our failure to maintain our qualification as a REIT for federal income tax purposes;

•changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs; and

•the impact of COVID-19 pandemic, or future pandemics, on us, our business, our tenants, or the economy generally.

While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and the related notes and the discussion under the heading

22

Table of Contents

"Management's Discussion and Analysis of Financial Condition and Results of Operations" for the fiscal year ended December 31, 2022 included in our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q.

This discussion, particularly information with respect to our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, includes forward-looking statements that involve risks and uncertainties as described under the heading "Special Note Regarding Forward-Looking Information" in this Quarterly Report on Form 10-Q. You should review the disclosure under the heading "Risk Factors" in our most recent annual report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from those anticipated in these forward-looking statements.

Overview

NewLake Capital Partners, Inc., ("the “Company,” "we," "our," "us,") is an internally managed REIT and a leading provider of real estate capital to state-licensed cannabis operators primarily through sale-leaseback transactions, third-party purchases and funding for build-to-suit projects. Our properties are leased to single tenants on a long-term, triple-net basis, which obligates the tenant for the ongoing expenses of the leased property, in addition to its rent obligations.

We were incorporated in Maryland on April 9, 2019. We conduct our business through a traditional umbrella partnership REIT structure, in which properties are owned by an operating partnership, directly or through subsidiaries. We are the sole general partner of our operating partnership and currently own approximately 98% of the OP Units. We have elected to be taxed as a REIT for U.S. federal income tax purposes beginning with our short taxable year ended December 31, 2019 and intend to operate our business so as to continue to qualify as a REIT.

On March 17, 2021, we consummated a merger pursuant to which we combined our company with a separate company, or the Target, that owned a portfolio of cultivation facilities and dispensaries utilized in the cannabis industry, and renamed ourselves “NewLake Capital Partners, Inc.” The Merger was completed through the issuance of 7,699,887 shares of common stock valued at $21.15 per share and warrants to purchase up to 602,392 shares of the Company’s common stock valued at approximately $4.8 million. The Company also incurred approximately $2.1 million in merger-related transaction costs. The consideration issued was based upon the relative value of the two entities, such that the shareholders of the Company and the Target, immediately prior to the Merger, owned 56.79% and 43.21%, respectively, of the outstanding post-merger common stock of the Company. The Company issued warrants to Target shareholders based on the pre-merger options outstanding, using the equivalent proportion described in the previous sentence. Upon completion of the Merger, we owned 24 properties across nine states. In connection with the Merger, we also entered into various arrangements and agreements with certain of our significant stockholders, including director nomination rights.

On August 13, 2021, we completed our initial public offering ("IPO") of 3,905,950 shares of our common stock, par value $0.01 per share at a public offering price of $26.00 per share for gross proceeds of approximately $102.0 million, before deducting placement agent fees and offering expenses. Net proceeds were approximately $93.5 million. Our common stock trades on the OTCQX® Best Market operated by the OTC Markets Group, Inc., under the symbol “NLCP”.

As of March 31, 2023, we owned a geographically diversified portfolio consisting of 32 properties across 12 states with 13 tenants, comprised of 17 dispensaries and 15 cultivation facilities.

Emerging Growth Company

We have elected to be an emerging growth company, as defined in the JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company, among other things:

•We are exempt from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;

•We are permitted to provide less extensive disclosure about our executive compensation arrangements; and

•We are not required to give our stockholders non-binding advisory votes on executive compensation or golden parachute arrangements.

23

Table of Contents

We have elected to use an extended transition period for complying with new or revised accounting standards.

We may take advantage of the other provisions for up to five years or such earlier time that we are no longer an emerging growth company. We will cease to be an emerging growth company upon the earliest to occur of: (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.2 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the exchange, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

Factors Impacting Our Operating Results

Our results of operations are affected by a number of factors and depend on the rental revenue we receive from the properties that we own, interest income we receive from the loans we originate, the timing of lease expirations, general market conditions, the regulatory environment in the cannabis industry, and the competitive environment for real estate assets that support the cannabis industry.

Rental Revenues

We receive income from rental revenue generated from our real estate properties that we own and expect to acquire in the future. The amount of rental revenue depends upon a number of factors, including:

•Our ability to enter into new leases at market value rents inclusive of annual rent increases; and

•Rent collection, which primarily relates to each of our current and future tenant’s or guarantor’s financial condition and ability to make rent payments to us on time.

The properties that we own consist of real estate assets that support the cannabis industry. Changes in current favorable state or local laws in the cannabis industry may impair our ability to renew or re-lease properties and the ability of our tenants to fulfill their lease obligations could materially and adversely affect our ability to maintain or increase rental rates for our properties.

Commencing in November 2022, we allowed one of our tenants, Hero Diversified Associates, Inc. ("Calypso") to remit their rent payments weekly and we expect to continue allowing weekly rental payments for the foreseeable future.

As of March 31, 2023, we had one tenant, Revolutionary Clinics, Inc., that has not paid rent for the quarter. We have applied a quarter of their security deposit to their first quarter rent. We will continue to assess and apply the security deposit quarterly, as needed.We are currently in discussion with the tenant to negotiate a resolution, which could include rent deferrals, or other concessions.

Market Conditions

Recently, financial markets have been volatile, reflecting heightened geopolitical risks, material tightening of financial conditions since the U.S. Federal Reserve began increasing interest rates in the spring of 2022. Regional bank have come under pressure resulting in the failure of three U.S. regional banks. The uncertainty continues to pummel the banking industry, despite assurances from financial regulators and bankers the health of the banking system remains strong. This volatility in the financial markets has led to continued uncertainty regarding monetary policy, the banking industry and concerns of an economic recession. The current market conditions have reduced the availability of capital for us and our tenants.

Inflation and Supply Chain Constraints

Inflation continues to trend significantly higher than in prior periods, which may be negatively impacting some of our tenants. This inflation has impacted costs for labor and production inputs for regulated cannabis operators, in addition to increasing costs of construction for development and redevelopment projections. Ongoing labor shortages and global supply chain issues, geopolitical issues and the war in Ukraine, also continue to adversely impact costs and timing for

24

Table of Contents

completion of these development and redevelopment projects, which are resulting in cost overruns and delays in commencing operations on certain of our tenants' projects.

Competitive Environment

We face competition from a diverse mix of market participants, including but not limited to, other companies with similar business models, independent investors, hedge funds and other real estate investors, mortgage REITs, hard money lenders, as well as would-be tenants and cannabis operators themselves, all of whom may compete with us in our efforts to acquire real estate zoned for cannabis cultivation, production or dispensary operations. Competition from others may diminish our opportunities to acquire a desired property on favorable terms or at all. In addition, this competition may put pressure on us to reduce the rental rates below those that we expect to charge for the properties that we own and expect to acquire, which would adversely affect our financial results.

Financial Performance and Condition of Our Tenants

For the period ended March 31, 2023, all of our rental revenues were derived from triple-net leases to 13 tenants. Our leases obligate the tenant for all the ongoing expenses of a property, including real estate taxes, insurance, maintenance and utilities, in addition to its rent obligations and include a parent or other affiliate guarantee. Our revenues are, therefore, dependent on our tenants (and related guarantors) ability to meet their respective obligations to us. Our tenants operate in the regulated cannabis industry, which is an evolving and highly regulated space. Further, because the regulated cannabis industry is a relatively new space, some of our existing tenants have limited operating histories and may be more susceptible to payment and other lease defaults. Thus, our operating results will be significantly impacted by the ability of our tenants to achieve and sustain positive financial results.

Critical Accounting Policies and Estimates

In accordance with generally accepted accounting principles in the United State of America, ("GAAP"), our consolidated financial statements require the use of estimates and assumptions that involve the exercise of judgment and use of assumptions. Our most critical accounting policies will involve decisions and assessments that could affect our reported assets and liabilities, as well as our reported revenues and expenses. Actual results could differ materially from those estimates and assumptions.

We believe that all of the decisions and assessments upon which our consolidated financial statements have been based were reasonable at the time made and based upon information available to us at that time. There have been no significant changes to our critical accounting estimates that were disclosed in our most recent Annual Report on Form 10-K for the year ended December 31, 2022.

Q1 2023 Highlights

Investment Activity

Real Estate Acquisitions

As of March 31, 2023, we owned a geographically diversified portfolio consisting of 32 properties across 12 states with 13 tenants, comprised of 17 dispensaries and 15 cultivation facilities with a weighted average remaining lease term of 14.6 years. All of our leases, and the secured loan, include a parent or other affiliate guarantee.

The following table presents the Company's investment activity for the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Closing Date	Real Estate Acquisition Costs
Bloom Medicinal	Missouri	Cultivation	March 3, 2023	$	350	(1)
Total				$	350

(1) The Company exercised its option to purchase the adjacent parcel of land to expand our cultivation facility in Missouri and have committed to fund $16.2 million for the expansion.

25

Table of Contents

The following table presents the tenant improvements funded during the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Acquisition Closing Date	Tenant Improvements Funded			Unfunded Commitments
Mint	Arizona	Cultivation	June 24, 2021	$	752	(1)	$	802
Organic Remedies	Missouri	Cultivation	December 20, 2021	116			166
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	534			16,150
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—			750
Total				$	1,402		$	17,868

(1)The tenant has been paying rent on the remaining commitment since July 2022 in accordance with the lease agreement.

Financing Activity

Seller Financing

In January 2023 we made our annual principal payment of $1.0 million. The loan's outstanding balance as of March 31, 2023 was $1.0 million and the remaining unamortized discount was $10.2 thousand. The final principal payment is due in January 2024.

Revolving Credit Facility

The outstanding borrowings under the Revolving Credit Facility were $1.0 million as March 31, 2023. Refer to Note 6 in the Notes to Consolidated Financial Statements in Part I – Item 1 for further information.

Capital Markets Activity

Stock Repurchase Program

On November 7, 2022, our board of directors approved a repurchase program of up to $10.0 million of our common stock through December 31, 2023. For the three months ended March 31, 2023, pursuant to the repurchase plan, we acquired 49,307 shares of common stock with an average price, including commissions, of $12.63, totaling approximately $622 thousand.

Recent Developments

Tenant Improvements

The Company funded approximately $0.8 million of tenant improvements to our cultivation facility located in Phoenix, Arizona subsequent to quarter end.

Results of Operations

General

We derive substantially all our revenue from rents received from single tenants of each of our properties under triple-net leases. Our triple-net leases obligate the tenant for all the ongoing expenses of a property, including real estate taxes, insurance, maintenance and utilities, in addition to its rent obligations. Our leases also typically include annual rent escalations (typically within the range of 2-3%) as a set percentage or based on an inflation index, which generally provides us with contractual revenue growth and inflation-protected returns. All of our leases include a parent or other affiliate guarantee.

26

Table of Contents

Comparison of the three months ended March 31, 2023 and 2022 (in thousands):

	For the Three Months Ended March 31,				Increase/(Decrease)
	2023		2022		Q1'23 vs Q1'22
Revenue:
Rental Income	$	11,157	$	9,097	$	2,060
Interest Income from Loans	128		919		(791)
Fees and Reimbursables	131		150		(19)
Total Revenue	11,416		10,166		1,250
Expenses:
Depreciation and Amortization Expense	3,561		2,679		882
General and Administrative Expenses:
Compensation expense	819		836		(17)
Stock-Based Compensation	308		405		(97)
Professional fees	322		541		(219)
Other general and administrative expenses	564		532		32
Total general and administrative expenses	2,013		2,314		(301)
Total Expenses	5,574		4,993		581
Loss on Sale of Real Estate	—		(60)		60
Income From Operations	5,842		5,113		729
Other Income (Expenses):
Interest Income	220		48		172
Interest Expense	(92)		(27)		(65)
Total Other Income (Expense)	128		21		107
Net Income	5,970		5,134		836
Net Income Attributable to Noncontrolling Interests	(102)		(117)		15
Net Income Attributable to Common Stockholders	$	5,868	$	5,017	$	851

Revenues

Rental Income

Rental income for the three months ended March 31, 2023 increased by approximately $2.1 million to approximately $11.2 million, compared to approximately $9.1 million for the three months ended March 31, 2022. The increase in rental income was primarily attributable to:

•A full quarter of rental income from three cultivation facilities, including one cultivation facility that converted from a mortgage loan to a 20 year sale-leaseback, and one dispensary, acquired subsequent to the first quarter of 2022, which generated approximately $1.9 million of rental income during the three months ended March 31, 2023.

27

Table of Contents

•Rental income increased from tenant improvements at our Arizona, Florida and Missouri cultivation facilities which generated approximately $1.0 million of additional rental income during the three months ended March 31, 2023.

•Annual escalations on our portfolio generated an increase of approximately $0.2 million of rental revenue during the three months ended March 31, 2023.

The increase in rental revenue was partially offset by a decrease of approximately $1.0 million in rental income mainly attributable to one non-performing tenant Revolutionary Clinics, that failed to pay contractual rent under its lease agreement. We held a security deposit of approximately three months of contractual rent. In the first quarter of 2023, we applied 25% or $315 thousand of the security deposit towards the outstanding rent. We continue to monitor the situation and are in discussions with the tenant to negotiate a resolution, which might include rent deferrals or potentially releasing the property to a new tenant. Also, to a lesser extent the sale of one of our properties in Massachusetts also contributed to the partial offset in the increase in rental income.

Interest Income from Loans

The decrease in interest income from loans of approximately $0.8 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022, was attributable to the conversion of the $30.0 million mortgage loan we entered into during the fourth quarter of 2021 that converted to a 20 year sale-leaseback, in accordance with the loan agreement, on August 5, 2022. We also recognized approximately $128.1 thousand of interest income in connection with a $5.0 million unsecured loan that was originated on June 10, 2022, in connection with the purchase of a Missouri cultivation facility.

Expenses

Depreciation and Amortization Expense

Depreciation and amortization expense for the three months ended March 31, 2023, increased by approximately $882 thousand to approximately $3.6 million compared to $2.7 million for the three months ended March 31, 2022. The increase in depreciation was attributable to: (i) the acquisition of three cultivation facilities and one dispensary; (ii) the mortgage loan that converted to a twenty year sale-leaseback property on August 5, 2022; (iii) the expansion at an existing cultivation facility in Florida; and (iv) approximately $22.2 million of improvements that were placed into service subsequent to March 31, 2022.

General and Administrative Expense

Total general and administrative expenses for the three months ended March 31, 2023 decreased by approximately $301 thousand, to $2.0 million, compared to $2.3 million for the three months ended March 31, 2022. The decrease in general and administrative expense is described below by category.

Compensation Expense

Compensation expense was relatively flat quarter over quarter.

Stock Based Compensation

Stock-based compensation expense was relatively flat quarter over quarter. See Note 9 - Stock Based Compensations for additional details.

Professional Fees

Professional fees for the three months ended March 31, 2023, decreased by approximately $219 thousand to approximately $322 thousand, compared to $541 thousand for the three months ended March 31, 2022. The decrease was mainly attributable to approximately $163 thousand related to the elimination of outsourced accounting functions, we did not incur recruiting fees in the first quarter of 2023 which resulted in a decrease of approximately $55 thousand and a decline in legal fees associated with a potential restructuring of approximately $94 thousand, offset by an increase in general legal fees of approximately $60 thousand.

28

Table of Contents

Other General and Administrative Expenses

For the three months ended March 31, 2023, other general and administrative expenses increased by approximately $32 thousand to approximately $564 thousand, compared to $532 thousand for the three months ended March 31, 2022. Other general and administrative expenses is comprised of director and officer insurance, information technology, public relations fees and various other expenses. The increase was mainly attributable to higher public relations fees, information technology costs and corporate rent, offset by lower director and officer insurance costs.

Loss on Sale of Real Estate

For the three months ended March 31, 2023 we did not sell any properties.

On March 21, 2022, we sold our PharmaCann Massachusetts property for approximately $800 thousand. We recognized a loss on sale of the property of $60 thousand during the three months ended March 31, 2022.

Other Income (Expense)

Interest income increased during the three months ended March 31, 2023 by approximately $172 thousand, to $220 thousand compared to $48 thousand for the three months ended March 31, 2022, primarily due to higher interest rates on our cash balances in our money market accounts.

Interest expense increased during the three months ended March 31, 2023, to $92 thousand, compared to $27 thousand for the three months ended March 31, 2022. The increase was mainly a result of a withdrawal of $1.0 million from the Revolving Credit Facility we entered into on May 6, 2022, and the associated non-cash interest expense of approximately $64 thousand related to the amortization of deferred financing costs incurred in connection with this facility.

Non-GAAP Financial Information and Other Metrics

Funds from Operations and Adjusted Funds from Operations

FFO and AFFO are non-GAAP financial measures and should not be viewed as alternatives to net income calculated in accordance with GAAP as a measurement of our operating performance. We believe that FFO and AFFO are useful to investors because they are widely accepted industry measures used by analysts and investors to compare the operating performance of REITs.

We calculate FFO in accordance with the current National Association of Real Estate Investment Trusts (“NAREIT”) definition. NAREIT currently defines FFO as follows: net income (loss) (computed in accordance with GAAP) excluding depreciation and amortization related to real estate, gains and losses from the sale of certain real estate assets, and impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by an entity. Other REITs may not define FFO in accordance with the NAREIT definition or may interpret the current NAREIT definition differently than we do and therefore our computation of FFO may not be comparable to such other REITs.

We calculate AFFO by starting with FFO and adding back non-cash and certain non-recurring transactions, including non-cash components of compensation expense and our internalization costs. Other REITs may not define AFFO in the same manner as we do and therefore our calculation of AFFO may not be comparable to such other REITs. You should not consider FFO and AFFO to be alternatives to net income as a reliable measure of our operating performance; nor should you consider FFO and AFFO to be alternatives to cash flows from operating, investing or financing activities (as defined by GAAP) as measures of liquidity.

29

Table of Contents

The table below is a reconciliation of net income attributable to common stockholders to FFO and AFFO for the three months ended March 31, 2023 and 2022 (in thousands):

	For the Three Months Ended March 31,
	2023		2022
Net Income Attributable to Common Stockholders	$	5,868	$	5,017
Net Income Attributable to Noncontrolling Interests	102		117
Net Income Attributable to Common Stockholders - Diluted	5,970		5,134
Adjustments:
Real Estate Depreciation and Amortization	3,561		2,679
Loss on Sale of Real Estate	—		60
FFO Attributable to Common Stockholders - Diluted (1)	9,531		7,873
Stock-Based Compensation	308		405
Non-cash Interest Expense	68		7
AFFO Attributable to Common Stockholders - Diluted (1)	$	9,907	$	8,285
(1) The first quarter 2023 FFO diluted and AFFO diluted are calculated and presented on a fully diluted basis and comparative prior period balances for FFO and AFFO were calculated to conform to the first quarter 2023 presentation.

Liquidity and Capital Resources

Our cash requirements include the payment of dividends, to our shareholders, distributions to our OP Unit holders, general and administrative expenses, debt service, other expenses related to managing our existing portfolio as well as acquisition and unfunded tenant improvement costs. The sources of liquidity to fund these cash requirements include rental revenue from the leasing of our properties, which is our primary source of cash flow, borrowings under our revolving credit facility and equity and debt issuances either in the public or private markets, if markets permit. Where possible, we also may issue OP Units to acquire properties from existing owners seeking a tax-deferred transaction.

As of March 31, 2023, we had $130.5 million of liquidity comprised of $41.5 million of cash and cash equivalents and $89.0 million available on our $90.0 million revolving credit facility. The ongoing challenges posed by the increase in interest rates and inflation could adversely impact our cash flow from continuing operations but we expect that cash flow from continuing operations over the next twelve months, together with cash on hand, will be adequate to fund our business operations, cash dividends to our shareholders, distributions to our OP Unit holders and debt service. Acquisitions and unfunded tenant improvement costs may require funding from borrowings, equity issuance and/or issuance of OP units. We cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to us in sufficient amounts in the future.

Summary of Cash Flows

The following summary discussion of our cash flows is based on the consolidated statements of cash flows in our consolidated financial statements and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below (in thousands):

	For the Three Months Ended March 31, 2023		For the Three Months Ended March 31, 2022
Net Cash Provided by Operating Activities	$	8,237	$	6,237
Net Cash Used in Investing Activities	$	(1,752)	$	(9,982)
Net Cash Used in Financing Activities	$	(10,179)	$	(8,564)
Cash and Cash Equivalents - End of Period	$	41,498	$	114,788

30

Table of Contents

Net Cash Provided by Operating Activities:

Net cash provided by operating activities for the three months ended March 31, 2023 and 2022 were approximately $8.2 million and $6.2 million, respectively. Net cash flows provided by operating activities for the three months ended March 31, 2023 primarily related to contractual rent, partially offset by our general and administrative expenses. Net cash flows provided by operating activities for the three months ended March 31, 2022 primarily related to contractual rent and security deposits from our properties, partially offset by our general and administrative expenses.

Net Cash Used in Investing Activities:

Cash used in investing activities for the three months ended March 31, 2023 and net cash used in investing activities for the three months ended March 31, 2022 were approximately $1.8 million and $10.0 million, respectively. Cash used in investing activities for the three months ended March 31, 2023 related to approximately $350 thousand used to purchase an adjacent parcel of land by an existing cultivation facility in Missouri and approximately $1.4 million of funded tenant improvements. Net cash used in investing activities for the three months ended March 31, 2022 related to $7.3 million placed in escrow to purchase a cultivation facility in Missouri on April 1, 2022 and approximately $3.4 million of funded tenant improvements, partially offset by approximately $0.8 million of proceeds received from sale of our Franklin, Massachusetts property.

Cash Used in Financing Activities:

Cash used in financing activities for the three months ended March 31, 2023 and cash used in financing activities for the three months ended March 31, 2022 were approximately $10.2 million and $8.6 million, respectively. Cash used in financing activities for the three months ended March 31, 2023, were related to approximately $8.5 million in dividend payments to holders of our common stock, as well as distributions to OP Units and RSU holders, $1.0 million to pay down our loan payable, approximately $622 thousand to buy back stock under the stock repurchase program and approximately $45 thousand in deferred financing costs related to obtaining our Revolving Credit Facility. Cash used in financing activities for the three months ended March 31, 2022 were related to approximately $6.8 million in dividend payments to holders of our common stock, as well as distributions to OP Units and RSU holders and $1.8 million to pay down our loan payable.

Dividends

To maintain our qualification as a REIT, U.S. federal income tax law generally requires that we distribute at least 90% of our REIT taxable income annually, determined without regard to the deduction for dividends paid and excluding capital gains. We must pay tax at regular corporate rates to the extent that we annually distribute less than 100% of our taxable income. We evaluate each quarter to determine our ability to pay dividends to our stockholders based on our net taxable income if and to the extent authorized by our board of directors. Before we pay any dividend, whether for U.S. federal income tax purposes or otherwise, we must first meet both our operating requirements and debt service payments. If our cash available for distribution is less than our net taxable income, we could be required to sell assets or borrow funds to make cash distributions or we may make a portion of the required distribution in the form of a taxable stock distribution.

As a result of this distribution requirement, our Operating Partnership cannot rely on retained earnings to fund its ongoing operations to the same extent that other companies whose parent companies are not REITs can. During the three months ended March 31, 2023, we declared and our board of directors approved, cash dividends on our common stock and restricted stock units and in our capacity as general partner of the Operating Partnership, authorized distributions on our OP Units totaling $0.39 per share. During the three months ended March 31, 2022, we declared and our board of directors approved, cash dividends on our common stock and restricted stock units and in our capacity as general partner of the Operating Partnership, authorized distributions on our OP Units totaling approximately $0.33 per share.

Contractual Obligations and Commitments

Unfunded Commitments

As of March 31, 2023, the Company had aggregate unfunded commitments to invest $17.9 million to develop and improve our existing cultivation facilities in Arizona, Missouri, and Pennsylvania.

31

Table of Contents

Corporate Office Lease

As of March 31, 2023, the Company is the lessee under one office lease for a term of four years, subject to annual escalations. The annual rent payments range from approximately $72 thousand in year one to $85 thousand in year four.

Revolving Credit Facility

As of March 31, 2023, the Company had $1.0 million drawn on our Revolving Credit Facility which bears interest at a rate of 5.65% per annum.

Adoption of New or Revised Accounting Standards

We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recent Accounting Pronouncements

Refer to Note 2 in the Notes to Consolidated Financial Statements in Part I – Item 1 for a discussion of accounting guidance recently adopted by the Company or expected to be adopted by the Company in the future.

Interest Rate Risk

Interest rates are highly sensitive to many factors, including fiscal and monetary policies and domestic and international economic and political considerations, as well as other factors beyond our control. We are subject to interest rate risk in connection with our Revolving Credit Facility. As of March 31, 2023, we had $1.0 million principal drawn on our Revolving Credit Facility, at a fixed interest rate of 5.65% through May 2025 and a floating rate thereafter. Therefore, if interest rates decrease, our required payments may exceed those based on current market rates.

Impact of Inflation

The U.S. economy has experienced an increase in inflation rates recently. We enter into leases that generally provide for annual fixed increases in rent at a fixed rate. In some instances, leases provide for annual increases in rent based on the increase in annual CPI. We expect these lease provisions to result in rent increases over time. During times when inflation is greater than increases in rent, as provided for in the leases, rent increases may not keep up with the rate of inflation.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

In the commercial real estate market, property prices generally continue to fluctuate. Likewise, during certain periods, the U.S. credit markets have experienced significant price volatility, dislocations, and liquidity disruptions, which may impact our access to and cost of capital. We continually monitor the commercial real estate and U.S. credit markets carefully and, if required, will make decisions to adjust our business strategy accordingly.

ITEM 4. CONTROLS AND PROCEDURES.

Our management, including our Chief Executive Officer (the CEO) and Chief Financial Officer (the CFO), reviewed and evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act) as of the end of the period covered by this report. Based on that review and evaluation, the CEO and CFO have concluded that our current disclosure controls and procedures, as designed, (1) were effective in ensuring that information required to be disclosed by the Company in reports it files or submits under the Securities Exchange Act is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure and (2) were effective in ensuring that information

32

Table of Contents

required to be disclosed by the Company in reports it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms. There have been no changes in our internal controls over financial reporting that occurred during the three months ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Limitations on Controls

Our system of internal control over financial reporting was designed to provide reasonable assurance regarding the preparation and fair presentation of published financial statements in accordance with accounting principles generally accepted in the United States. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

33

Table of Contents

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

We are not currently a party to any material legal proceedings. From time to time, we may in the future be a party to various claims and routine litigation arising in the ordinary course of business.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors set forth in the section titled “Risk Factors” included in our Annual Report on Form 10-K, dated March 9, 2023, filed with the SEC. Our business involves significant risks. You should carefully consider the risks and uncertainties described in our Annual Report on Form 10-K, together with all of the other information in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report. The risks and uncertainties described in our Annual Report are not the only ones we face. Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price of our common stock could decline and you could lose part or all of your investment.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On November 7, 2022, our board of directors authorized a common stock repurchase program, to repurchase up to $10.0 million of our outstanding common stock (the “Repurchase Program”). Such authorization has an expiration date of December 31, 2023. The purchases totaling 49,307 shares of common stock with an average price, including commissions, of $12.63 for approximately $622 thousand were made in the open market in accordance with Rule 10b-18 of the Securities and Exchange Act of 1934. The remaining availability under the program as of March 31, 2023 was approximately $9.4 million.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURE.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

34

Table of Contents

Item 6. Exhibits

EXHIBIT INDEX

Exhibit Number	Description
3.1	Articles of Amendment and Restatement of NewLake Capital Partners, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-11 filed on June 21, 2021).
3.2	Articles Supplementary of NewLake Capital Partners, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on September 19, 2022).
3.3	Amended and Restated Bylaws of NewLake Capital Partners, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant's Quarterly Report on Form 10-Q filed on November 10, 2022).
31.1*	Certification of the Chief Executive Officer under Section 302 of the Sarbanes-OxleyAct of 2002.
31.2*	Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document.
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

_______________________

†Management contracts or compensatory plans required to be filed as Exhibits to this Form 10-Q.

*Filed herewith.

35

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NEWLAKE CAPITAL PARTNERS, INC.
Dated: May 10, 2023	By:	/s/ Anthony Conilgio
		Name: Anthony Coniglio
		Title: President and Chief Executive Officer
		(Principal Executive Officer)
Dated: May 10, 2023	By:	/s/ Lisa Meyer
		Name: Lisa Meyer
		Title: Chief Financial Officer, Treasurer and Secretary
		(Principal Financial Officer and Principal Accounting Officer)

36

EX-31.1

Exhibit31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF1934, AS ADOPTED PURSUANT TO SECTION302 OF THE

SARBANES-OXLEY ACT OF2002

I, Anthony Coniglio, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2023	By:	/s/ Anthony Coniglio
		Anthony Coniglio
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2

Exhibit31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF1934, AS ADOPTED PURSUANT TO SECTION302 OF THE

SARBANES-OXLEY ACT OF2002

I, Lisa Meyer, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2023	By:	/s/ Lisa Meyer
		Lisa Meyer
		Chief Financial Officer, Treasurer and Secretary
		(Principal Financial Officer)

EX-32.1

Exhibit32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION1350,

AS ADOPTED PURSUANT TO

SECTION906 OF THE SARBANES-OXLEY ACT OF2002

In connection with the Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc. (the “Company”) for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Anthony Coniglio, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

It is not intended that this statement be deemed to be filed for purposes of the Securities Exchange Act of 1934.

Date: May 10, 2023	By:	/s/ANTHONY CONIGLIO
		Anthony Coniglio
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-32.2

Exhibit32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION1350,

AS ADOPTED PURSUANT TO

SECTION906 OF THE SARBANES-OXLEY ACT OF2002

In connection with the Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc. (the “Company”) for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Lisa Meyer, Chief Financial Officer, Treasurer and Secretary of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

It is not intended that this statement be deemed to be filed for purposes of the Securities Exchange Act of 1934.

Date: May 10, 2023	By:	/s/ Lisa Meyer
		Lisa Meyer
		Chief Financial Officer, Treasurer and Secretary
		(Principal Financial Officer)

XML

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 09, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	000-56327
Entity Registrant Name	NewLake Capital Partners, Inc.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	83-4400045
Entity Address, Address Line One	50 Locust Avenue, First Floor
Entity Address, City or Town	New Canaan
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06840
City Area Code	203
Local Phone Number	594-1402
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,358,887
Entity Central Index Key	0001854964
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Amendment Flag	false

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Real Estate
Land	$ 21,397	$ 21,427
Building and Improvements	377,880	378,047
Total Real Estate	399,277	399,474
Less Accumulated Depreciation	(22,796)	(19,736)
Net Real Estate	376,481	379,738
Cash and Cash Equivalents	41,498	45,192
In-Place Lease Intangible Assets, net	21,268	21,765
Loan Receivable	5,000	5,000
Property Held for Sale	1,949	0
Other Assets	2,260	2,554
Total Assets	448,456	454,249
Liabilities:
Accounts Payable and Accrued Expenses	1,274	1,659
Revolving Credit Facility	1,000	1,000
Loan Payable, net	990	1,986
Dividends and Distributions Payable	8,483	8,512
Security Deposits	7,469	7,774
Rent Received in Advance	651	1,375
Other Liabilities	478	1,005
Total Liabilities	20,345	23,311
Commitments and Contingencies
Equity:
Preferred Stock, $0.01 Par Value, 100,000,000 Shares Authorized, 0 and 0 Shares Issued and Outstanding, Respectively	0	0
Common Stock, $0.01 Par Value, 400,000,000 Shares Authorized, 21,358,887 and 21,408,194 Shares Issued and Outstanding, Respectively	214	214
Additional Paid-In Capital	455,470	455,822
Accumulated Deficit	(34,956)	(32,487)
Total Stockholders' Equity	420,728	423,549
Noncontrolling Interests	7,383	7,389
Total Equity	428,111	430,938
Total Liabilities and Equity	$ 448,456	$ 454,249

XML

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	400,000,000	400,000,000
Common Stock, Shares Issued (in shares)	21,358,887	21,408,194
Common Stock, Shares Outstanding (in shares)	21,358,887	21,408,194

XML

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Rental Income	$ 11,157	$ 9,097
Interest Income from Loans	128	919
Fees and Reimbursables	131	150
Total Revenue	11,416	10,166
Expenses:
Depreciation and Amortization Expense	3,561	2,679
General and Administrative Expenses:
Compensation Expense	819	836
Stock-Based Compensation	308	405
Professional fees	322	541
Other General and Administrative Expenses	564	532
Total General and Administrative Expenses	2,013	2,314
Total Expenses	5,574	4,993
Loss on Sale of Real Estate	0	(60)
Income From Operations	5,842	5,113
Other Income (Expenses):
Investment Income, Interest	220	48
Interest Expense	(92)	(27)
Total Other Income (Expense)	128	21
Net Income	5,970	5,134
Net Income Attributable to Noncontrolling Interests	(102)	(117)
Net Income Attributable to Common Stockholders	$ 5,868	$ 5,017
Net Income Attributable to Common Stockholders Per Share - Basic (in dollars per share)	$ 0.27	$ 0.24
Net Income Attributable to Common Stockholders Per Share - Diluted (in dollars per share)	$ 0.27	$ 0.23
Weighted Average Shares of Common Stock Outstanding - Basic (in shares)	21,423,470	21,382,069
Weighted Average Shares of Common Stock Outstanding - Diluted (in shares)	21,797,316	21,931,352

XML

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2021		21,235,914
Beginning balance at Dec. 31, 2021	$ 439,335	$ 213	$ 450,916	$ (23,574)	$ 11,780
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Vested RSUs to Common Stock (in shares)		3,002
Conversion of Vested RSUs to Common Stock	0		126		(126)
Conversion of OP Units to Common Stock (in shares)		61,494
Conversion of OP Units to Common Stock	0		1,104		(1,104)
Stock-Based Compensation	405		405
Dividends to Common Stock	(7,029)			(7,029)
Dividend Equivalents to Restricted Stock Units	(42)				(42)
Distributions to OP Unit Holders	(129)				(129)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	0		139		(139)
Net Income	5,134			5,017	117
Ending balance (in shares) at Mar. 31, 2022		21,300,410
Ending balance at Mar. 31, 2022	437,674	$ 213	452,690	(25,586)	10,357
Beginning balance (in shares) at Dec. 31, 2022		21,408,194
Beginning balance at Dec. 31, 2022	$ 430,938	$ 214	455,822	(32,487)	7,389
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of OP Units to Common Stock (in shares)		0
Repurchase of Common Stock (in shares)	(49,307)	(49,307)
Repurchase of Common Stock	$ (622)		(622)
Stock-Based Compensation	308		308
Dividends to Common Stock	(8,330)			(8,330)
Dividend Equivalents to Restricted Stock Units	(7)			(7)
Distributions to OP Unit Holders	(146)				(146)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	0		(38)		38
Net Income	5,970			5,868	102
Ending balance (in shares) at Mar. 31, 2023		21,358,887
Ending balance at Mar. 31, 2023	$ 428,111	$ 214	$ 455,470	$ (34,956)	$ 7,383

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Cash Flows from Operating Activities:
Net Income	$ 5,970	$ 5,134
Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities:
Stock-Based Compensation	308	405
Loss on Sale of Real Estate	0	60
Depreciation and Amortization Expense	3,557	2,679
Amortization of Debt Issuance Costs	64	0
Amortization of Debt Discount	3	7
Changes in Assets and Liabilities
Other Assets	259	(121)
Accounts Payable and Accrued Expenses	(383)	(685)
Security Deposits	(305)	0
Interest Reserve	0	(919)
Rent Received in Advance	(724)	(323)
Other Liabilities	(512)	0
Net Cash Provided by Operating Activities	8,237	6,237
Cash Flows from Investing Activities:
Escrow Deposits	0	(7,300)
Reimbursements of Tenant Improvements	(1,402)	(3,443)	$ (45,245)
Acquisition of Real Estate	(350)	0
Disposition of Real Estate	0	761
Net Cash Used in Investing Activities	(1,752)	(9,982)
Cash Flows from Financing Activities:
Repurchase of Common Stock	(622)	0
Common Stock Dividends Paid	(8,349)	(6,593)
Restricted Stock Units Dividend Equivalents Paid	(17)	(42)
Distributions to OP Unit Holders	(146)	(129)
Principal Repayment on Loan Payable	(1,000)	(1,800)
Deferred Financing Costs	(45)	0
Net Cash Used in Financing Activities	(10,179)	(8,564)
Net Increase (Decrease) in Cash and Cash Equivalents	(3,694)	(12,309)
Cash and Cash Equivalents - Beginning of Period	45,192	127,097	127,097
Cash and Cash Equivalents - End of Period	41,498	114,788	45,192
Supplemental Disclosure of Cash Flow Information:
Interest Paid	94	5
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Dividends and Distributions Declared, Not Paid	$ 8,483	$ 7,200	$ 8,512

XML

Organization

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Organization

NewLake Capital Partners, Inc. (the “Company”), a Maryland corporation, was formed on April 9, 2019, under the Maryland General Corporation Law, as GreenAcreage Real Estate Corp. (“GARE”). The Company is an internally managed Real Estate Investment Trust (“REIT”) focused on providing long-term, single-tenant, triple-net sale-leaseback and build-to-suit transactions for the cannabis industry. The Company’s year-end is December 31. On March 17, 2021, GARE completed a merger (the “Merger”) with another company (the “Target”) that owned a portfolio of cultivation facilities and dispensaries utilized in the cannabis industry, and renamed itself “NewLake Capital Partners, Inc.” The Merger was completed through the issuance of 7,699,887 shares of common stock valued at $21.15 per share and warrants to purchase up to 602,392 shares of the Company’s common stock valued at approximately $4.8 million. Upon completion of the Merger, the Company owned 24 properties across nine states. In connection with the Merger, the Company also entered into various arrangements and agreements with certain of the Company's significant stockholders, including director nomination rights.

The Company conducts its business through its subsidiary, NLCP Operating Partnership LP, a Delaware limited partnership (the “Operating Partnership” or “OP”). The Company holds an equity interest in the Operating Partnership and is the sole general partner. Subsequent to the Merger, the name of the Operating Partnership was changed from GreenAcreage Operating Partnership LP to NLCP Operating Partnership LP.

On August 13, 2021, the Company completed its initial public offering ("IPO") of 3,905,950 shares of common stock, with a par value $0.01 per share. The Company's common stock trades on the OTCQX® Best Market operated by the OTC Markets Group, Inc., under the symbol “NLCP”.

XML

Basis of Presentation and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of the Company, the Operating Partnership, as well as wholly owned subsidiaries of the Operating Partnership’s and variable interest entities ("VIEs") in which the Company is considered the primary beneficiary. The accompanying unaudited financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. In managements opinion, all adjustments (which include only normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the full year or any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and filed with the Securities and Exchange Commission (“SEC”) on March 9, 2023.

Substantially all of the Company's asset are held by and all of its' operations are conducted through the Operating Partnership. The Company is the sole managing general partner of the Operating Partnership. Noncontrolling investors in the Operating Partnership are included in Noncontrolling Interest in the Company's consolidated financial statements. Refer to Note 8 for details. The Operating Partnership is a VIE because the holders of limited partnership interests do not have substantive kick-out rights or participating rights. Furthermore, the Company is the primary beneficiary of the Operating Partnership because it has the obligation to absorb losses and the right to receive benefits from the Operating Partnership and the exclusive power to direct the activities of the Operating Partnership. As of March 31, 2023 and December 31, 2022, the assets and liabilities of

the Company and the Operating Partnership are substantially the same, as the Company does not have any significant assets other than its investment in the Operating Partnership.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management will adjust such estimates when facts and circumstances dictate. Such estimates include, but are not limited to, useful lives for depreciation of property, the fair value and impairment of property and in-place lease intangibles acquired, and the fair value of stock-based compensation. Actual results could differ from those estimates.

Reclassification

Certain prior year balances have been reclassified to conform to the Company's current year presentation.

Significant Accounting Policies

There have been no significant changes to the Company's accounting polices included in Note 2 to the Consolidated Financial Statements of the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

Recent Accounting Pronouncements

Description	Adoption Date	Effect on Financial Statements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments — Credit Losses, which among other updates, clarifies that receivables arising from operating leases are not within the scope of this guidance and should be evaluated in accordance with Topic 842.	January 1, 2023	The adoption of this standard did not have a material impact on the Company’s consolidated financial statements due to the limited nature of financial assets held by the Company subject to ASU 2016-13.

XML

Real Estate

3 Months Ended

Mar. 31, 2023

Real Estate [Abstract]

Real Estate

Real Estate

As of March 31, 2023, the Company owned 32 properties, including one that is classified as held for sale, located in 12 states. The following table presents the Company's held for investment real estate portfolio as of March 31, 2023 (dollars in thousands):

Tenant		Market	Site Type	Land		Building and Improvements		Total Real Estate		Accumulated Depreciation		Net Real Estate
Acreage		Connecticut	Dispensary	$	395	$	534	$	929	$	(62)	$	867
Acreage		Massachusetts	Cultivation	481		9,310		9,791		(953)		8,838
Acreage		Pennsylvania	Cultivation	952		9,209		10,161		(910)		9,251
Ayr Wellness, Inc.		Nevada	Cultivation	1,002		12,577		13,579		(297)		13,282
Ayr Wellness, Inc.		Pennsylvania	Cultivation	2,964		11,565		14,529		(314)		14,215
Bloom Medicinal		Missouri	Cultivation	948		11,919		12,867		(232)		12,635
Calypso Enterprises		Pennsylvania	Cultivation	1,486		28,514		30,000		(668)		29,332
Columbia Care		California	Dispensary	1,082		2,692		3,774		(176)		3,598
Columbia Care		Illinois	Dispensary	162		1,053		1,215		(66)		1,149
Columbia Care		Illinois	Cultivation	801		10,560		11,361		(673)		10,688
Columbia Care		Massachusetts	Dispensary	108		2,212		2,320		(156)		2,164
Columbia Care		Massachusetts	Cultivation	1,136		12,690		13,826		(1,079)		12,747
Cresco Labs		Illinois	Cultivation	276		50,456		50,732		(4,643)		46,089
Curaleaf		Connecticut	Dispensary	184		2,748		2,932		(187)		2,745
Curaleaf		Florida	Cultivation	388		75,595		75,983		(4,649)		71,334
Curaleaf		Illinois	Dispensary	69		525		594		(37)		557
Curaleaf		Illinois	Dispensary	65		959		1,024		(70)		954
Curaleaf		Illinois	Dispensary	606		1,128		1,734		(81)		1,653
Curaleaf		Illinois	Dispensary	281		3,072		3,353		(214)		3,139
Curaleaf		North Dakota	Dispensary	779		1,395		2,174		(102)		2,072
Curaleaf		Ohio	Dispensary	574		2,788		3,362		(226)		3,136
Curaleaf		Pennsylvania	Dispensary	877		1,041		1,918		(95)		1,823
Curaleaf		Pennsylvania	Dispensary	216		2,011		2,227		(140)		2,087
Greenlight	(1)	Arkansas	Dispensary	238		1,919		2,157		(134)		2,023
Mint	(2)	Arizona	Cultivation	2,400		11,293		13,693		—		13,693
Organic Remedies		Missouri	Cultivation	204		20,731		20,935		(1,369)		19,566
PharmaCann		Massachusetts	Dispensary	411		1,701		2,112		(209)		1,903
PharmaCann		Ohio	Dispensary	281		1,269		1,550		(15)		1,535
PharmaCann		Pennsylvania	Dispensary	44		1,271		1,315		(81)		1,234
Revolutionary Clinics		Massachusetts	Cultivation	926		41,934		42,860		(2,164)		40,696
Trulieve		Pennsylvania	Cultivation	1,061		43,209		44,270		(2,794)		41,476
Total Real Estate(3)				$	21,397	$	377,880	$	399,277	$	(22,796)	$	376,481

Note 3 - Real Estate (continued)

(1) GL Partners, Inc. (Greenlight) took over as tenant, however Curaleaf remains the guarantor subject to certain conditions in the lease agreement.

(2) This property is under development. Once completed and placed in service, the Company will start depreciating this property.

(3) The table does not include one property held for sale.

Real Estate Acquisitions

During the three months ended March 31, 2023, the Company invested approximately $350 thousand to acquire one parcel of land and committed to fund $16.2 million to expand a cultivation facility in Missouri . The following table presents the real estate acquisition for the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Closing Date	Real Estate Acquisition Costs
Bloom Medicinal	Missouri	Cultivation	March 3, 2023	$	350	(1)
Total				$	350

(1)The Company exercised its option to purchase the adjacent parcel of land to expand its cultivation facility in Missouri and has committed to fund $16.2 million for the expansion.

During the year ended December 31, 2022, the Company invested approximately $67.0 million to acquire four cultivation facilities and one dispensary. The following table presents the real estate acquisitions for the year ended December 31, 2022 (in thousands):

Tenant	Market	Site Type	Closing Date	Real Estate Acquisition Costs(1)
Bloom Medicinal	Missouri	Cultivation	April 01, 2022	7,301		(2)
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	14,529
Ayr Wellness, Inc.	Nevada	Cultivation	June 30, 2022	13,579
Calypso Enterprises	Pennsylvania	Cultivation	August 05, 2022	30,000		(3)
PharmaCann	Ohio	Dispensary	November 03, 2022	1,550
Total				$	66,959

(1)     Includes the purchase price (and in some cases, transaction costs that have been capitalized into the purchase price) and TI commitments funded at closing, if any, as of December 31, 2022. Excludes TI commitments not funded as of December 31, 2022. Excludes approximately $11.0 thousand of capitalized transaction costs on properties purchased prior to January 1, 2022.

(2)      Includes approximately $5.0 million of TI funded at closing of the property.

(3)     The Company entered into a $30.0 million mortgage loan on October 29, 2021 which converted to a sale-leaseback on August 5, 2022.

Conversion of Mortgage Loan

The Company funded a $30.0 million mortgage loan to Hero Diversified Associates, Inc. (“HDAI" or "Calypso") on October 29, 2021. On August 5, 2022 the mortgage loan converted to a twenty year sale-leaseback and the Company recorded land and building and improvements which have been included in "Total Real Estate" on the consolidated balance sheets.

Note 3 - Real Estate (continued)

Tenant Improvements Funded

During the three months ended March 31, 2023, the Company funded approximately $1.4 million of tenant improvements. The following table presents the tenant improvements funded for the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Closing Date	TI Funded		Unfunded Commitments
Mint	Arizona	Cultivation	June 24, 2021	$	752	$	802	(1)
Organic Remedies	Missouri	Cultivation	December 20, 2021	116		166
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	534		16,150
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—		750
Total				$	1,402	$	17,868

(1)The tenant has been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.

During the year ended December 31, 2022, the Company funded approximately $45.2 million of tenant improvements. The following table presents the tenant improvements funded for the year ended December 31, 2022 (in thousands):

Tenant	Market	Site Type	Closing Date	TI Funded			Unfunded Commitments
Curaleaf	Florida	Cultivation	August 4, 2020	$	20,983	'(1)	$	—
Mint	Massachusetts	Cultivation	April 1, 2021	349			—
Mint	Arizona	Cultivation	June 24, 2021	7,415			1,554		'(2)
PharmaCann	Massachusetts	Dispensary	March 17, 2021	25			—
Trulieve	Pennsylvania	Cultivation	March 17, 2021	7,046		'(3)	—
Organic Remedies	Missouri	Cultivation	December 20, 2021	4,745			282
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	4,682			534		'(4)
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—			750
Total				$	45,245		$	3,120
(1) On June 16, 2022, the Company funded the expansion of an existing property.
(2) The tenant has been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.
(3) The tenant had been paying rent for the TI since December 2021 in accordance with the lease agreement. As of May 2022, the TI had been fully funded.
(4) The unfunded commitment does not include a $16.5 million option but not obligation to acquire an adjacent property from an existing tenant.

Disposal of Real Estate

There were no sales of real estate during the three months ended March 31, 2023.

On March 21, 2022, the Company sold one of its Massachusetts properties for approximately $0.8 million, which was leased to PharmaCann. The Company recognized a loss on sale of the property of $60 thousand. The Company continued to collect the rent that would have been received from the Massachusetts property through increased lease payments from each of the remaining two properties leased by PharmaCann until the acquisition of a third property that was leased to PharmaCann in November 2022.

Note 3 - Real Estate (continued)

Real Estate Held for Sale

As of March 31, 2023, the Company is under contract with a broker to sell a property with a carrying amount $1.9 million located in Massachusetts. The property is available for immediate sale in its present condition and management expects the property will sell within one year. A property that is held for sale is required to be recorded at the lower of carrying amount or fair value less cost to sell with a loss recognized if the carrying amount of the property exceeds its fair value less cost to sell. As of March 31, 2023, the property was recorded at its carry value as a result of a make whole provision in the lease agreement.

At March 31, 2023, the property's initial recording amount was $1.9 million and it is classified in "Property Held for Sale" in the accompanying consolidated balance sheet.

Construction in Progress

Construction in progress was $12.9 million and $12.1 million on March 31, 2023 and December 31, 2022, respectively, and is included in "Buildings and Improvements" in the accompanying consolidated balance sheets.

Depreciation and Amortization

Depreciation expense for the three months ended March 31, 2023 and 2022, was $3.1 million and $2.2 million, respectively.

Amortization of the Company’s acquired in-place lease intangible assets was approximately $0.5 million for both the three months ended March 31, 2023 and 2022. The acquired in-place lease intangible assets have a weighted average remaining amortization period of 10.9 years.

In-place Leases

The following table presents the future amortization of the Company’s acquired in-place leases as of March 31, 2023 (in thousands):

Year	Expense
2023 (nine months ending December 31, 2023)	$	1,489
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$	21,268

Impairment

The Company reviewed tenant activities and changes in the business condition of all of its properties and reviewed the existence of potential triggering events or impairment indicators to determine if there is impairment. Based on its review, as of March 31, 2023 and March 31, 2022 no impairment losses were recognized.

XML

Leases

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

Leases

Leases

As Lessor

The Company's properties are leased to single tenants on a long-term, triple-net basis, which obligates the tenant to be responsible for the ongoing expenses of a property, in addition to its rent obligations. The Company's tenants operate in the fast-growing cannabis industry. All of the Company's leases generally contain annual increases in rent (typically between 2% and 3%) over the expiring rental rate at the time of expiration. Certain of the Company's leases also contain a Tenant Improvement Allowance (“TIA”). TIA is generally available to be funded between 12 and 18 months. In some leases, the tenant becomes liable to pay rent as if the full TIA has been funded, even if there are still unfunded commitments. TIA also contains annual increases which generally increase at the same rate as base rent, per the lease agreement. Certain of the Company's leases provide the lessee with a right of first refusal or right of first offer in the event the Company markets the leased property for sale. Two of the Company’s leases that were entered into in December 2020 provide the lessee with a purchase option to purchase the leased property at the end of the initial lease term in December 2029, subject to the satisfaction of certain conditions. The purchase option provision allows the lessee to purchase the leased property for an amount based on the fair market value of the Company's investment. As of March 31, 2023, the Company's gross investment in these two properties was approximately $6.3 million.

The following table presents the future contractual minimum rent under the Company’s operating leases as of March 31, 2023 (in thousands):

Year	Contractual Minimum Rent
2023 (nine months ending December 31, 2023)	$	36,889
2024	51,211
2025	53,405
2026	54,777
2027	56,186
Thereafter	593,151
Total	$	845,619

Concentration of Credit Risk

The ability of any of the Company's tenants to honor the terms of its lease are dependent upon the economic, regulatory, competitive, natural and social factors affecting the community in which that tenant operates.

Note 4 - Leases (continued)

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's total rental income for each of the periods presented:

For the Three Months Ended March 31,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		11	26%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	'(3)	1	14%
Calypso	1	'(2)	8%	Columbia Care		5	11%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(2) This tenant held a mortgage loan as of the three months ended March 31, 2022, therefore the Company received interest income rather than rental income during that period. In August 2022, the mortgage loan converted to a twenty year sale-leaseback.

(3) This tenant failed to pay rental income during the three months ended March 31, 2023. A security deposit of approximately $315 thousand was applied.

Non-Performing Tenant

Through March 31, 2023, Revolutionary Clinics failed to pay contractual rent, under one lease agreement. The Company is currently in discussion with the tenant to negotiate a resolution, which could include rent deferrals, or other concessions. The Company held a security deposit of approximately three months of contractual rent, of which we applied $315 thousand towards the outstanding rent during the three months ended March 31, 2023.

As Lessee

As of March 31, 2023, the Company was the lessee under one office lease that qualifies under the right-of-use ("ROU") model. The Company recorded a ROU asset of $273 thousand which is classified in “Other Assets” on the Company's consolidated balance sheets through a ROU model, in which the Company recorded a ROU asset and a lease liability. The ROU asset is amortized over the remaining lease term. The amortization is made up of the principal amortization under the lease liability plus or minus the straight-line adjustment of the operating lease rent. The lease liability is included in “Other Liabilities” the Company's consolidated balance sheets.

The following table presents the future contractual rent obligations as lessee as of March 31, 2023 (in thousands):

Year	Contractual Base Rent
2023	$	59
2024	75
2025	77
2026	52
Total Minimum Lease Payments	$	263
Less Amount Discounted Using Incremental Borrowing Rate	48
Total Lease Liability	$	215

Note 4 - Leases (continued)

As of March 31, 2023, the weighted-average discount rate used to calculate the lease liability was 5.65% and the remaining lease term was 3.4 years.

Leases

Leases

As Lessor

The Company's properties are leased to single tenants on a long-term, triple-net basis, which obligates the tenant to be responsible for the ongoing expenses of a property, in addition to its rent obligations. The Company's tenants operate in the fast-growing cannabis industry. All of the Company's leases generally contain annual increases in rent (typically between 2% and 3%) over the expiring rental rate at the time of expiration. Certain of the Company's leases also contain a Tenant Improvement Allowance (“TIA”). TIA is generally available to be funded between 12 and 18 months. In some leases, the tenant becomes liable to pay rent as if the full TIA has been funded, even if there are still unfunded commitments. TIA also contains annual increases which generally increase at the same rate as base rent, per the lease agreement. Certain of the Company's leases provide the lessee with a right of first refusal or right of first offer in the event the Company markets the leased property for sale. Two of the Company’s leases that were entered into in December 2020 provide the lessee with a purchase option to purchase the leased property at the end of the initial lease term in December 2029, subject to the satisfaction of certain conditions. The purchase option provision allows the lessee to purchase the leased property for an amount based on the fair market value of the Company's investment. As of March 31, 2023, the Company's gross investment in these two properties was approximately $6.3 million.

The following table presents the future contractual minimum rent under the Company’s operating leases as of March 31, 2023 (in thousands):

Year	Contractual Minimum Rent
2023 (nine months ending December 31, 2023)	$	36,889
2024	51,211
2025	53,405
2026	54,777
2027	56,186
Thereafter	593,151
Total	$	845,619

Concentration of Credit Risk

The ability of any of the Company's tenants to honor the terms of its lease are dependent upon the economic, regulatory, competitive, natural and social factors affecting the community in which that tenant operates.

Note 4 - Leases (continued)

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's total rental income for each of the periods presented:

For the Three Months Ended March 31,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		11	26%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	'(3)	1	14%
Calypso	1	'(2)	8%	Columbia Care		5	11%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(2) This tenant held a mortgage loan as of the three months ended March 31, 2022, therefore the Company received interest income rather than rental income during that period. In August 2022, the mortgage loan converted to a twenty year sale-leaseback.

(3) This tenant failed to pay rental income during the three months ended March 31, 2023. A security deposit of approximately $315 thousand was applied.

Non-Performing Tenant

Through March 31, 2023, Revolutionary Clinics failed to pay contractual rent, under one lease agreement. The Company is currently in discussion with the tenant to negotiate a resolution, which could include rent deferrals, or other concessions. The Company held a security deposit of approximately three months of contractual rent, of which we applied $315 thousand towards the outstanding rent during the three months ended March 31, 2023.

As Lessee

As of March 31, 2023, the Company was the lessee under one office lease that qualifies under the right-of-use ("ROU") model. The Company recorded a ROU asset of $273 thousand which is classified in “Other Assets” on the Company's consolidated balance sheets through a ROU model, in which the Company recorded a ROU asset and a lease liability. The ROU asset is amortized over the remaining lease term. The amortization is made up of the principal amortization under the lease liability plus or minus the straight-line adjustment of the operating lease rent. The lease liability is included in “Other Liabilities” the Company's consolidated balance sheets.

The following table presents the future contractual rent obligations as lessee as of March 31, 2023 (in thousands):

Year	Contractual Base Rent
2023	$	59
2024	75
2025	77
2026	52
Total Minimum Lease Payments	$	263
Less Amount Discounted Using Incremental Borrowing Rate	48
Total Lease Liability	$	215

Note 4 - Leases (continued)

As of March 31, 2023, the weighted-average discount rate used to calculate the lease liability was 5.65% and the remaining lease term was 3.4 years.

XML

Loan Receivable	3 Months Ended
	Mar. 31, 2023
Loans and Leases Receivable Disclosure [Abstract]
Loan Receivable	Loan ReceivableThe Company funded a $5.0 million unsecured loan to Bloom Medicinals on June 10, 2022. The loan initially bore interest at a rate of 10.25% and is structured to increase annually in April by the product of 1.0225 times the rate in effect immediately prior to the anniversary date. The loan can be prepaid at any time without penalty and matures on June 30, 2026. The loan is cross defaulted with their lease agreement with the Company. As of March 31, 2023, the aggregate principal amount outstanding on the unsecured loan receivable was $5.0 million.

XML

Financings

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Financings

Financings

Seller Financing

In connection with the purchase and leaseback of a cultivation facility in Chaffee, Missouri on December 20, 2021, the Company entered into a $3.8 million loan payable to the seller, which is an independent third party from the tenant. The loan bears interest at a rate of 4.0% per annum. Principal on the loan is payable in annual installments of which $1.8 million and $1.0 million were paid in January 2022 and January 2023, respectively. The remaining principal of $1.0 million is payable in January 2024. The loan's outstanding balance as of March 31, 2023 was $1.0 million and the remaining unamortized discount was $10.2 thousand.

Revolving Credit Facility

On May 6, 2022, the Company's Operating Partnership entered into a loan and security agreement (the “Loan and Security Agreement”) with a commercial federally regulated bank, as a lender and as agent for lenders that become party thereto from time to time (the “Agent”). The Loan and Security Agreement matures on May 6, 2027. The Loan and Security Agreement provides, subject to the Accordion Feature described below, $30.0 million in aggregate commitments for secured revolving loans (“Revolving Credit Facility”), the availability of which is based on a borrowing base consisting of fee simple owned real properties that satisfy eligibility criteria specified in the Loan and Security Agreement and the lease income thereunder which are owned by certain subsidiaries of the Operating Partnership.

On July 29, 2022, the Operating Partnership, entered into an amendment to the Revolving Credit Facility, amending the Loan and Security Agreement, to increase the aggregate commitment under the Revolving Credit Facility from $30.0 million to $90.0 million and added two additional lenders. The Loan and Security Agreement also allows the Company, subject to certain conditions, to request additional revolving incremental loan commitments such that the Revolving Credit Facility may be increased to a total aggregate principal amount of up to $100.0 million. Borrowings under the Revolving Credit Facility may be voluntarily prepaid and re-borrowed, subject to certain fees.

The Revolving Credit Facility bears a fixed rate of 5.65% for the first three years and thereafter a variable rate based upon the greater of (a) the Prime Rate quoted in the Wall Street Journal (Western Edition) (“Base Rate”) plus an applicable margin of 1.0% or (b) 4.75%.

As of March 31, 2023, the Company had approximately $1.0 million in borrowings under the Revolving Credit Facility and $89.0 million in funds available to be drawn, subject to sufficient collateral in the borrowing base.

The facility is subject to certain liquidity and operating covenants and includes customary representations and warranties, affirmative and negative covenants and events of default. As of March 31, 2023, the Company complied with the terms of such covenants.

XML

Related Party Transactions

3 Months Ended

Mar. 31, 2023

Related Party Transactions [Abstract]

Related Party Transactions

Related Party Transactions

Merger Agreement

In connection with the Merger, the Company entered into an Investor Rights Agreement (the "Investor Rights Agreement"). The Investor Rights Agreement provides the stockholders party thereto with certain rights with respect to the nomination of members to the Company's board of directors. Prior to the completion of the Company's IPO, pursuant to the Investor Rights Agreement, HG Vora Capital Management, LLC (“HG Vora”) had the right to nominate four directors to our board of directors. Following the completion of our IPO, for so long as HG Vora owns (i) at least 9% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate two of the members of our board of directors, and (ii) at least 5% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate one member of our board of directors. If HG Vora owns less than 5% of our issued and outstanding common stock for 60 consecutive days, then HG Vora may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Prior to the completion of our IPO, NLCP Holdings, LLC had the right to designate three directors to our board of directors. Subsequent to our IPO, NLCP Holdings, LLC no longer has these rights.

Prior to the completion of our IPO, West Investment Holdings, LLC, West CRT Heavy, LLC, Gary and Mary West 2012 Gift Trust, Gary and Mary West Charitable Trust and WFI Co-Investments acting unanimously, collectively referred to as the “West Stockholders,” did not have a director nomination right. Following the completion of our IPO, the West Stockholders may nominate one member of our board of directors for so long as the West Stockholders own in the aggregate at least 5% of the issued and outstanding shares of our common stock. If the West Stockholders own in the aggregate less than 5% of our issued and outstanding common stock for 60 consecutive days, then the West Stockholders may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Prior to the completion of our IPO, NL Ventures, LLC (“Pangea”) did not have a director nomination right. Following the completion of our IPO, Pangea may nominate one member of our board of directors for so long as Pangea owns at least 4% of our issued and outstanding common stock for 60 consecutive days. If Pangea owns less than 4% of our issued and outstanding common stock for 60 consecutive days, then Pangea may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

XML

Noncontrolling Interests

3 Months Ended

Mar. 31, 2023

Noncontrolling Interest [Abstract]

Noncontrolling Interests

Noncontrolling Interests

The Company's noncontrolling interests represent limited partnership interest in the Operating Partnership not held by the Company. Noncontrolling interests represented 1.7% and 1.8% ownership in the Operating Partnership at March 31, 2023 and March 31, 2022, respectively.

The following table presents the activity for the Company’s noncontrolling interests issued by the Operating Partnership;

	Three Months Ended March 31, 2023			Three Months Ended March 31, 2022
		OP Units	Noncontrolling Interests %	OP Units	Noncontrolling Interests %
Balance at January 1,		373,582	1.7%	453,303	2.1	%
OP Units Converted		—		(61,494)
Balance at March 31,		373,582	1.7%	391,809	1.8	%

XML

Stock Based Compensation

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stock Based Compensation

Stock Based Compensation

The Company's board of directors adopted the 2021 Equity Incentive Plan (the “Plan”), to provide employees of the Company and its subsidiaries, certain consultants and advisors who perform services for the Company or its subsidiaries, and non-employee members of the board of directors of the Company with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards to enable us to motivate, attract and retain the services of directors, officers and employees considered essential to the long term success of the Company. Under the terms of the Plan, the aggregate number of shares of awards will be no more than 2,275,727 shares. If and to the extent shares of awards granted under the Plan, expire or are canceled, forfeited, exchanged or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards are forfeited, terminated or otherwise not paid in full, the shares subject to such grants shall again be available for issuance or transfer under the Plan. The Plan has a term of ten years until August 12, 2031. As of March 31, 2023, there were approximately 1,943,936 shares available for issuance under the Plan.

Restricted Stock Units

During the three months ended March 31, 2023, the Company granted 27,630 RSUs to certain officers and employees of the Company. Total outstanding RSUs as of March 31, 2023 were 75,419. Of the 75,419 outstanding RSUs, 18,534 RSUs were fully vested and 56,885 RSUs were unvested. There were no RSUs that vested or were forfeited during the three months ended March 31, 2023. During the three months ended March 31, 2022, 1,044 RSUs were granted and 4,102 RSUs were forfeited. Total outstanding RSUs as of March 31, 2022 were 169,136. Of the 169,136 outstanding RSUs, 127,176 RSUs were fully vested and 41,960 RSUs were unvested. RSUs are subject to restrictions on transfer and may be subject to a risk of forfeiture if the award recipient ceases to be an employee or director of the Company prior to vesting of the award.

Each RSU represents the right to receive one share of common stock upon vesting. Each RSU is also entitled to receive a dividend equivalent payment equal to the dividend paid on one share of common stock upon vesting. Unearned dividend equivalents on unvested RSUs as of March 31, 2023 and 2022 were $60,760 and $26,854, respectively.

The amortization of compensation costs for the awards of RSUs are included in "Stock-Based Compensation" in the accompanying consolidated statements of operations and amounted to approximately $0.1 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively. The remaining unrecognized compensation cost of approximately $0.7 million for RSU awards is expected to be recognized over a weighted average amortization period of 1.6 years as of March 31, 2023.

The following table sets forth the Company's unvested restricted stock units activity for the three months ended March 31,:

	2023			2022
	Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	29,255	$	22.89	45,018	$	27.49
Granted	27,630	$	13.38	1,044	$	27.49
Forfeited	—	$	—	(4,102)	27.49
Balance at March 31,	56,885	$	18.27	41,960	$	27.49

Performance Stock Units

During the three months ended March 31, 2023, the Company granted 55,017 Performance Stock Units (“PSUs”) to officers and certain employees of the Company. Total outstanding PSUs as of March 31, 2023 and 2022 were 121,858 and 77,742, respectively. During the three months ended March 31, 2023 and 2022, no PSUs vested or were forfeited. PSUs vest subject to the achievement of relative total shareholder return as measured against a peer group of companies and absolute compounded annual growth in stock price during each performance period. The actual number of shares of common stock issued will range from 0 to 243,716 depending upon performance. The performance periods are August 13, 2021 through December 31, 2023, January 1, 2022 through December 31, 2024, and January 1, 2023 through December 31, 2025 and 18,858, 47,983 and 55,017 PSUs are scheduled to vest at the end of each performance period, respectively.

PSUs are recorded at fair value which involved using a Monte Carlo simulation for the future stock prices of the Company and its corresponding peer group. A fair value of $24.15, $24.00 and $11.23 were used for PSUs with performance periods ending December 31, 2023, 2024 and 2025, respectively. PSUs are subject to restrictions on transfer and may be subject to a risk of forfeiture if the award recipient ceases to be an employee of the Company prior to vesting of the award.

Each PSU is entitled to receive a dividend equivalent payment equal to the dividend paid on the number of shares of common stock issued per PSU vesting. Unearned dividend equivalents on unvested PSUs as of March 31, 2023 and 2022 were $164,496 and $49,755, respectively.

The amortization of compensation costs for the awards of PSUs are included in "Stock-Based Compensation" in the accompanying consolidated statements of operations and amounted to $0.2 million for the three months ended March 31, 2023 and 2022. The remaining unrecognized compensation cost of approximately $1.4 million for PSU awards is expected to be recognized over a weighted average amortization period of 2.1 years as of March 31, 2023.

The following table sets forth the Company's unvested performance stock activity for the three months ended March 31,:

	2023			2022
	Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	66,841	$	24.04	77,742	$	24.04
Granted	55,017	$	11.23	—	$	—
Balance at March 31,	121,858	$	18.26	77,742	$	24.04

Stock Options

Prior to the completion of the IPO, the Company issued 791,790 nonqualified stock options (the “Options”) to purchase shares of the Company’s common stock, subject to the terms and conditions of the applicable Option Grant Agreements, with an exercise price per share of common stock equal to $24.00 and in such amounts as set forth in the Option Grant Agreements. The Options vested on August 31, 2020 and were fully exercisable as of March 31, 2023. The options expire on July 15, 2027.

XML

Warrants

3 Months Ended

Mar. 31, 2023

Warrants and Rights Note Disclosure [Abstract]

Warrants

Warrants

On March 17, 2021, in connection with the Merger, the Company entered into a warrant agreement which granted the right to purchase 602,392 shares of common stock of the Company at a purchase price of $24.00 per share. Warrants are immediately exercisable and expire on July 15, 2027.

The following table summarizes warrant activity for the three months ended March 31,:

	2023			2022
	Number of Warrants	Weighted Average Exercise Price		Number of Warrants(1)	Weighted Average Exercise Price
Exercisable at January 1,	602,392	$	24.00	602,392	$	24.00
Granted	—	—		—	—
Exercised	—	—		—	—
Exercisable at March 31,	602,392	$	24.00	602,392	$	24.00

(1)Warrants granted on March 17, 2021.

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2023

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Stockholders' Equity

Preferred Stock

As of March 31, 2023, the Company had 100,000,000 shares of preferred stock authorized and 0 shares of preferred stock outstanding.

Common Stock

Stock Repurchase Program

On November 7, 2022, the board of directors of the Company authorized a stock repurchase program of its common stock up to $10.0 million through December 31, 2023. Purchases made pursuant to the stock repurchase program will be made in the open market, in privately negotiated transactions, or pursuant to any trading plan that may be adopted in accordance with Rule 10b-18 of the Securities and Exchange Act of 1934, as amended. The authorization of the stock repurchase program does not obligate the Company to acquire any particular amount of common stock. The timing, manner, price and amount of any repurchases will be determined by the Company in its discretion and will be subject to economic and market conditions, stock price, applicable legal requirements

and other factors. The stock repurchase program may be suspended or discontinued by us at any time and without prior notice.

For the three months ended March 31, 2023, pursuant to the repurchase plan, the Company acquired 49,307 shares of common stock with an average price, including commissions, of $12.63 totaling approximately $622 thousand. The remaining availability under the program as of March 31, 2023 was approximately $9.4 million

Conversion of OP Units

There were no OP Units converted during the three months ended March 31, 2023. During the three months ended March 31, 2022, 61,494 OP Units were converted one for one into our common stock.

Dividends

The following tables describe the cash dividends, dividend equivalents on vested RSUs and, in the Company's capacity as general partner of the operating partnership, authorized distributions on the Company's OP Units declared by the Company during the three months ended March 31, 2023 and 2022:

Declaration Date	Record Date	Period Covered	Distributions Paid Date	Amount per Share/Unit
March 7, 2023	March 31, 2023	January 1, 2023 to March 31, 2023	April 14, 2023	$	0.39
Total				$	0.39

Declaration Date	Record Date	Period Covered	Distributions Paid Date	Amount per Share/Unit
March 15, 2022	March 31, 2022	January 1, 2022 to March 31, 2022	April 14, 2022	$	0.33
Total				$	0.33

During the three months ended March 31, 2023 and 2022, the Company paid $8,685 and $1,436, respectively, of dividend equivalents that became earned upon vesting of RSUs. The Company had accrued unearned dividend equivalents on unvested RSUs and unvested PSUs of $225,256 and $76,609, as of March 31, 2023 and 2022, respectively.

XML

Earnings Per Share

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

The following table presents the computation of basic and diluted earnings per share (in thousands, except share data):

	For the Three Months Ended March 31,
	2023		2022
Numerator:
Net Income Attributable to Common Stockholders	$	5,868	$	5,017
Add: Net Income Attributable to Noncontrolling Interest	102		117
Net Income Attributable to Common Stockholders - Diluted	$	5,970	$	5,134
Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic	21,423,470		21,382,069
Dilutive Effect of OP Units	373,582		438,375
Dilutive Effect of Options and Warrants	—		65,099
Dilutive Effect of Unvested Restricted Stock Units	264		45,809
Weighted Average Shares of Common Stock - Diluted	21,797,316		21,931,352
Earnings Per Share - Basic
Net Income Attributable to Common Stockholders	$	0.27	$	0.24
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholders	$	0.27	$	0.23

During the three months ended March 31, 2023, the effect of including unvested restricted stock units and OP units were included in the Company's calculation of weighted average shares of common stock outstanding – diluted. The effect of outstanding stock options and outstanding warrants were excluded in the Company's calculation of weighted average shares of common stock outstanding – diluted as their inclusion would have been anti-dilutive. During the three months ended March 31, 2022, the effect of including OP Units, outstanding stock options, outstanding warrants and unvested restricted stock units were included in the Company's calculation of weighted average shares of common stock outstanding – diluted.

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standards describe three levels of inputs that may be used to measure fair value:

Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 – Includes other inputs that are directly or indirectly observable in the marketplace.

Level 3 – Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.

The following table presents the carrying value and estimated fair value of financial instruments at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023				December 31, 2022
	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Note Receivable(1)	$	5,000	$	4,907	$	5,000	$	4,952
Revolving Credit Facility(2)	$	1,000	$	905	$	1,000	$	915
Seller Financing(2)	$	990	$	959	$	1,986	$	1,942

(1) The fair value measurement of the $5.0 million Note Receivable is based on unobservable inputs, and as such, is classified as Level III.

(2) This fair value measurement of the Company’s Revolving Credit Facility and Seller Financing is based on observable inputs, and as such, are classified as Level II.

As of March 31, 2023 and December 31, 2022, the carrying amounts of financial instruments such as cash and cash equivalents, accounts payable and accrued expenses and other liabilities approximate their fair values due to their generally short-term nature and the market rates of interest of these instruments.

XML

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and ContingenciesAs of March 31, 2023, the Company had aggregate unfunded commitments to invest $17.9 million to develop and improve its' existing cultivation facilities in Arizona, Missouri, and Pennsylvania. Refer to Note 3 for further details on the Company's commitments. The Company owns a portfolio of properties that it leases to entities which cultivate, harvest, process and distribute cannabis. Cannabis is an illegal substance under the Controlled Substances Act. Although the operations of the Company’s tenants are legalized in the states and local jurisdictions in which they operate, the Company and its tenants are subject to certain risks and uncertainties associated with conducting operations subject to conflicting federal, state and local laws in an industry with a complex regulatory environment which is continuously evolving. These risks and uncertainties include the risk that the strict enforcement of federal laws regarding cannabis would likely result in the Company’s inability, and the inability of its tenants, to execute their respective business plans.

XML

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsTenant ImprovementsSubsequent to March 31, 2023, the Company funded approximately $0.8 million of tenant improvements to our cultivation facility located in Arizona.

XML

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The consolidated financial statements include the accounts of the Company, the Operating Partnership, as well as wholly owned subsidiaries of the Operating Partnership’s and variable interest entities ("VIEs") in which the Company is considered the primary beneficiary. The accompanying unaudited financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. In managements opinion, all adjustments (which include only normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the full year or any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and filed with the Securities and Exchange Commission (“SEC”) on March 9, 2023.

Substantially all of the Company's asset are held by and all of its' operations are conducted through the Operating Partnership. The Company is the sole managing general partner of the Operating Partnership. Noncontrolling investors in the Operating Partnership are included in Noncontrolling Interest in the Company's consolidated financial statements. Refer to Note 8 for details. The Operating Partnership is a VIE because the holders of limited partnership interests do not have substantive kick-out rights or participating rights. Furthermore, the Company is the primary beneficiary of the Operating Partnership because it has the obligation to absorb losses and the right to receive benefits from the Operating Partnership and the exclusive power to direct the activities of the Operating Partnership. As of March 31, 2023 and December 31, 2022, the assets and liabilities of

the Company and the Operating Partnership are substantially the same, as the Company does not have any significant assets other than its investment in the Operating Partnership.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management will adjust such estimates when facts and circumstances dictate. Such estimates include, but are not limited to, useful lives for depreciation of property, the fair value and impairment of property and in-place lease intangibles acquired, and the fair value of stock-based compensation. Actual results could differ from those estimates.

Reclassification

Reclassification

Certain prior year balances have been reclassified to conform to the Company's current year presentation.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Description	Adoption Date	Effect on Financial Statements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses, which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments — Credit Losses, which among other updates, clarifies that receivables arising from operating leases are not within the scope of this guidance and should be evaluated in accordance with Topic 842.	January 1, 2023	The adoption of this standard did not have a material impact on the Company’s consolidated financial statements due to the limited nature of financial assets held by the Company subject to ASU 2016-13.

XML

Real Estate (Tables)

3 Months Ended

Mar. 31, 2023

Real Estate [Abstract]

Properties Acquired and Current Properties

The following table presents the Company's held for investment real estate portfolio as of March 31, 2023 (dollars in thousands):

Tenant		Market	Site Type	Land		Building and Improvements		Total Real Estate		Accumulated Depreciation		Net Real Estate
Acreage		Connecticut	Dispensary	$	395	$	534	$	929	$	(62)	$	867
Acreage		Massachusetts	Cultivation	481		9,310		9,791		(953)		8,838
Acreage		Pennsylvania	Cultivation	952		9,209		10,161		(910)		9,251
Ayr Wellness, Inc.		Nevada	Cultivation	1,002		12,577		13,579		(297)		13,282
Ayr Wellness, Inc.		Pennsylvania	Cultivation	2,964		11,565		14,529		(314)		14,215
Bloom Medicinal		Missouri	Cultivation	948		11,919		12,867		(232)		12,635
Calypso Enterprises		Pennsylvania	Cultivation	1,486		28,514		30,000		(668)		29,332
Columbia Care		California	Dispensary	1,082		2,692		3,774		(176)		3,598
Columbia Care		Illinois	Dispensary	162		1,053		1,215		(66)		1,149
Columbia Care		Illinois	Cultivation	801		10,560		11,361		(673)		10,688
Columbia Care		Massachusetts	Dispensary	108		2,212		2,320		(156)		2,164
Columbia Care		Massachusetts	Cultivation	1,136		12,690		13,826		(1,079)		12,747
Cresco Labs		Illinois	Cultivation	276		50,456		50,732		(4,643)		46,089
Curaleaf		Connecticut	Dispensary	184		2,748		2,932		(187)		2,745
Curaleaf		Florida	Cultivation	388		75,595		75,983		(4,649)		71,334
Curaleaf		Illinois	Dispensary	69		525		594		(37)		557
Curaleaf		Illinois	Dispensary	65		959		1,024		(70)		954
Curaleaf		Illinois	Dispensary	606		1,128		1,734		(81)		1,653
Curaleaf		Illinois	Dispensary	281		3,072		3,353		(214)		3,139
Curaleaf		North Dakota	Dispensary	779		1,395		2,174		(102)		2,072
Curaleaf		Ohio	Dispensary	574		2,788		3,362		(226)		3,136
Curaleaf		Pennsylvania	Dispensary	877		1,041		1,918		(95)		1,823
Curaleaf		Pennsylvania	Dispensary	216		2,011		2,227		(140)		2,087
Greenlight	(1)	Arkansas	Dispensary	238		1,919		2,157		(134)		2,023
Mint	(2)	Arizona	Cultivation	2,400		11,293		13,693		—		13,693
Organic Remedies		Missouri	Cultivation	204		20,731		20,935		(1,369)		19,566
PharmaCann		Massachusetts	Dispensary	411		1,701		2,112		(209)		1,903
PharmaCann		Ohio	Dispensary	281		1,269		1,550		(15)		1,535
PharmaCann		Pennsylvania	Dispensary	44		1,271		1,315		(81)		1,234
Revolutionary Clinics		Massachusetts	Cultivation	926		41,934		42,860		(2,164)		40,696
Trulieve		Pennsylvania	Cultivation	1,061		43,209		44,270		(2,794)		41,476
Total Real Estate(3)				$	21,397	$	377,880	$	399,277	$	(22,796)	$	376,481

Note 3 - Real Estate (continued)

(1) GL Partners, Inc. (Greenlight) took over as tenant, however Curaleaf remains the guarantor subject to certain conditions in the lease agreement.

(2) This property is under development. Once completed and placed in service, the Company will start depreciating this property.

(3) The table does not include one property held for sale.

The following table presents the real estate acquisition for the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Closing Date	Real Estate Acquisition Costs
Bloom Medicinal	Missouri	Cultivation	March 3, 2023	$	350	(1)
Total				$	350

(1)The Company exercised its option to purchase the adjacent parcel of land to expand its cultivation facility in Missouri and has committed to fund $16.2 million for the expansion.

The following table presents the real estate acquisitions for the year ended December 31, 2022 (in thousands):

Tenant	Market	Site Type	Closing Date	Real Estate Acquisition Costs(1)
Bloom Medicinal	Missouri	Cultivation	April 01, 2022	7,301		(2)
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	14,529
Ayr Wellness, Inc.	Nevada	Cultivation	June 30, 2022	13,579
Calypso Enterprises	Pennsylvania	Cultivation	August 05, 2022	30,000		(3)
PharmaCann	Ohio	Dispensary	November 03, 2022	1,550
Total				$	66,959

(1)     Includes the purchase price (and in some cases, transaction costs that have been capitalized into the purchase price) and TI commitments funded at closing, if any, as of December 31, 2022. Excludes TI commitments not funded as of December 31, 2022. Excludes approximately $11.0 thousand of capitalized transaction costs on properties purchased prior to January 1, 2022.

(2)      Includes approximately $5.0 million of TI funded at closing of the property.

(3)     The Company entered into a $30.0 million mortgage loan on October 29, 2021 which converted to a sale-leaseback on August 5, 2022.

Tenant Improvements Funded

The following table presents the tenant improvements funded for the three months ended March 31, 2023 (in thousands):

Tenant	Market	Site Type	Closing Date	TI Funded		Unfunded Commitments
Mint	Arizona	Cultivation	June 24, 2021	$	752	$	802	(1)
Organic Remedies	Missouri	Cultivation	December 20, 2021	116		166
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	534		16,150
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—		750
Total				$	1,402	$	17,868

(1)The tenant has been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.

The following table presents the tenant improvements funded for the year ended December 31, 2022 (in thousands):

Tenant	Market	Site Type	Closing Date	TI Funded			Unfunded Commitments
Curaleaf	Florida	Cultivation	August 4, 2020	$	20,983	'(1)	$	—
Mint	Massachusetts	Cultivation	April 1, 2021	349			—
Mint	Arizona	Cultivation	June 24, 2021	7,415			1,554		'(2)
PharmaCann	Massachusetts	Dispensary	March 17, 2021	25			—
Trulieve	Pennsylvania	Cultivation	March 17, 2021	7,046		'(3)	—
Organic Remedies	Missouri	Cultivation	December 20, 2021	4,745			282
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	4,682			534		'(4)
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—			750
Total				$	45,245		$	3,120
(1) On June 16, 2022, the Company funded the expansion of an existing property.
(2) The tenant has been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.
(3) The tenant had been paying rent for the TI since December 2021 in accordance with the lease agreement. As of May 2022, the TI had been fully funded.
(4) The unfunded commitment does not include a $16.5 million option but not obligation to acquire an adjacent property from an existing tenant.

Future Amortization Expense

The following table presents the future amortization of the Company’s acquired in-place leases as of March 31, 2023 (in thousands):

Year	Expense
2023 (nine months ending December 31, 2023)	$	1,489
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$	21,268

XML

Leases (Tables)

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

Future Contractual Minimum Rent

The following table presents the future contractual minimum rent under the Company’s operating leases as of March 31, 2023 (in thousands):

Year	Contractual Minimum Rent
2023 (nine months ending December 31, 2023)	$	36,889
2024	51,211
2025	53,405
2026	54,777
2027	56,186
Thereafter	593,151
Total	$	845,619

Tenants in Portfolio that Represents the Largest Percentage of Total Revenue

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's total rental income for each of the periods presented:

For the Three Months Ended March 31,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		11	26%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	'(3)	1	14%
Calypso	1	'(2)	8%	Columbia Care		5	11%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(2) This tenant held a mortgage loan as of the three months ended March 31, 2022, therefore the Company received interest income rather than rental income during that period. In August 2022, the mortgage loan converted to a twenty year sale-leaseback.

(3) This tenant failed to pay rental income during the three months ended March 31, 2023. A security deposit of approximately $315 thousand was applied.

Operating Lease Maturity

The following table presents the future contractual rent obligations as lessee as of March 31, 2023 (in thousands):

Year	Contractual Base Rent
2023	$	59
2024	75
2025	77
2026	52
Total Minimum Lease Payments	$	263
Less Amount Discounted Using Incremental Borrowing Rate	48
Total Lease Liability	$	215

XML

Noncontrolling Interests (Tables)

3 Months Ended

Mar. 31, 2023

Noncontrolling Interest [Abstract]

Noncontrolling Interest Activity

The following table presents the activity for the Company’s noncontrolling interests issued by the Operating Partnership;

	Three Months Ended March 31, 2023			Three Months Ended March 31, 2022
		OP Units	Noncontrolling Interests %	OP Units	Noncontrolling Interests %
Balance at January 1,		373,582	1.7%	453,303	2.1	%
OP Units Converted		—		(61,494)
Balance at March 31,		373,582	1.7%	391,809	1.8	%

XML

Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Unvested Restricted Stock Activity

The following table sets forth the Company's unvested restricted stock units activity for the three months ended March 31,:

	2023			2022
	Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	29,255	$	22.89	45,018	$	27.49
Granted	27,630	$	13.38	1,044	$	27.49
Forfeited	—	$	—	(4,102)	27.49
Balance at March 31,	56,885	$	18.27	41,960	$	27.49

Unvested Performance Stock Activity

The following table sets forth the Company's unvested performance stock activity for the three months ended March 31,:

	2023			2022
	Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	66,841	$	24.04	77,742	$	24.04
Granted	55,017	$	11.23	—	$	—
Balance at March 31,	121,858	$	18.26	77,742	$	24.04

XML

Warrants (Tables)

3 Months Ended

Mar. 31, 2023

Warrants and Rights Note Disclosure [Abstract]

Warrant Activity

The following table summarizes warrant activity for the three months ended March 31,:

	2023			2022
	Number of Warrants	Weighted Average Exercise Price		Number of Warrants(1)	Weighted Average Exercise Price
Exercisable at January 1,	602,392	$	24.00	602,392	$	24.00
Granted	—	—		—	—
Exercised	—	—		—	—
Exercisable at March 31,	602,392	$	24.00	602,392	$	24.00

(1)Warrants granted on March 17, 2021.

XML

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2023

Stockholders' Equity Note [Abstract]

Common Dividends, Dividend Equivalents and Distributions Declared

The following tables describe the cash dividends, dividend equivalents on vested RSUs and, in the Company's capacity as general partner of the operating partnership, authorized distributions on the Company's OP Units declared by the Company during the three months ended March 31, 2023 and 2022:

Declaration Date	Record Date	Period Covered	Distributions Paid Date	Amount per Share/Unit
March 7, 2023	March 31, 2023	January 1, 2023 to March 31, 2023	April 14, 2023	$	0.39
Total				$	0.39

Declaration Date	Record Date	Period Covered	Distributions Paid Date	Amount per Share/Unit
March 15, 2022	March 31, 2022	January 1, 2022 to March 31, 2022	April 14, 2022	$	0.33
Total				$	0.33

XML

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Earnings Per Share

The following table presents the computation of basic and diluted earnings per share (in thousands, except share data):

	For the Three Months Ended March 31,
	2023		2022
Numerator:
Net Income Attributable to Common Stockholders	$	5,868	$	5,017
Add: Net Income Attributable to Noncontrolling Interest	102		117
Net Income Attributable to Common Stockholders - Diluted	$	5,970	$	5,134
Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic	21,423,470		21,382,069
Dilutive Effect of OP Units	373,582		438,375
Dilutive Effect of Options and Warrants	—		65,099
Dilutive Effect of Unvested Restricted Stock Units	264		45,809
Weighted Average Shares of Common Stock - Diluted	21,797,316		21,931,352
Earnings Per Share - Basic
Net Income Attributable to Common Stockholders	$	0.27	$	0.24
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholders	$	0.27	$	0.23

XML

Fair Value Measures and Disclosures (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Carrying Value and Estimated Fair Value of Financial Instruments

The following table presents the carrying value and estimated fair value of financial instruments at March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023				December 31, 2022
	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Note Receivable(1)	$	5,000	$	4,907	$	5,000	$	4,952
Revolving Credit Facility(2)	$	1,000	$	905	$	1,000	$	915
Seller Financing(2)	$	990	$	959	$	1,986	$	1,942

(1) The fair value measurement of the $5.0 million Note Receivable is based on unobservable inputs, and as such, is classified as Level III.

(2) This fair value measurement of the Company’s Revolving Credit Facility and Seller Financing is based on observable inputs, and as such, are classified as Level II.

XML

Organization (Details) $ / shares in Units, $ in Millions	Aug. 13, 2021 $ / shares shares	Mar. 17, 2021 USD ($) state property $ / shares shares	Mar. 31, 2023 property $ / shares	Dec. 31, 2022 $ / shares
Asset Acquisition [Line Items]
Number of properties | property			32
Common stock, par value (in dollars per share) | $ / shares			$ 0.01	$ 0.01
Merger with Target
Asset Acquisition [Line Items]
Shares issued during merger (in shares) | shares		7,699,887
Shares issued (in dollars per share) | $ / shares		$ 21.15
Merger with Target | NewLake Capital Partners Inc
Asset Acquisition [Line Items]
Number of properties | property		24
Number of states | state		9
Shares issued (in shares) | shares	3,905,950
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Merger with Target | Warrants Issued in Connection with the Merger
Asset Acquisition [Line Items]
Number of warrants to purchase (in shares) | shares		602,392
Warrants | $		$ 4.8

XML

Real Estate - Narrative (Details) $ in Thousands			3 Months Ended		12 Months Ended
	Aug. 05, 2022	Mar. 21, 2022 USD ($) property	Mar. 31, 2023 USD ($) property landParcel state	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) dispensary facility	Nov. 30, 2022 property	Oct. 29, 2021 USD ($)
Real Estate [Line Items]
Number of properties | property			32
Number of properties classified as held-for-sale | property			1
Number of states where real estate property is owned | state			12
Real estate acquisition costs			$ 350	$ 0
Unfunded commitments			17,868		$ 3,120
Number of cultivation facilities acquired | facility					4
Number of acquired dispensaries | dispensary					1
Loans receivable			5,000		$ 5,000
Payments for tenant improvements			1,402	3,443	45,245
Proceeds from sale			0
Real estate held for sale			1,949		0
Depreciation expense			3,100	2,200
Amortization of in-place lease intangible assets			500	500
Impairment loss			0	$ 0
Wholly Owned Properties
Real Estate [Line Items]
Real estate acquisition costs			$ 350		66,959
HDAI | Mortgage Receivable
Real Estate [Line Items]
Loans receivable							$ 30,000
Sale lease back term (in years)	20 years
Cultivation Facility In Missouri
Real Estate [Line Items]
Number of parcel of land acquired | landParcel			1,000
Unfunded commitments			$ 16,200
Leases, Acquired-in-Place
Real Estate [Line Items]
Acquired in-place lease intangible asset weighted average remaining amortization period (in years)			10 years 10 months 24 days
Building and Improvements
Real Estate [Line Items]
Construction in progress			$ 12,900		$ 12,100
PharmaCann Massachusetts Property
Real Estate [Line Items]
Number of properties | property		2				3
Number of properties sold | property		1
Proceeds from sale		$ 800
Loss on sale		$ 60

XML

Real Estate - Properties Acquired and Current Properties (Details)		3 Months Ended		12 Months Ended
	Apr. 01, 2022 USD ($)	Mar. 31, 2023 USD ($) property	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Mar. 03, 2023 USD ($)	Jan. 01, 2022 USD ($)	Oct. 29, 2021 USD ($)
Real Estate [Line Items]
Land		$ 21,397,000		$ 21,427,000
Building and Improvements		377,880,000		378,047,000
Total Real Estate		399,277,000		399,474,000
Accumulated Depreciation		(22,796,000)		(19,736,000)
Net Real Estate		$ 376,481,000		379,738,000
Number of properties classified as held-for-sale | property		1
Real Estate Acquisition Costs		$ 350,000	$ 0
Payments for tenant improvements		1,402,000	$ 3,443,000	45,245,000
Loans receivable		5,000,000		5,000,000
Cultivation Facility In Missouri
Real Estate [Line Items]
Commitment to fund expansion					$ 16,200,000
Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs		350,000		66,959,000
Capitalized transaction costs						$ 11,000
Acreage | Connecticut | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		395,000
Building and Improvements		534,000
Total Real Estate		929,000
Accumulated Depreciation		(62,000)
Net Real Estate		867,000
Acreage | Massachusetts | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		481,000
Building and Improvements		9,310,000
Total Real Estate		9,791,000
Accumulated Depreciation		(953,000)
Net Real Estate		8,838,000
Acreage | Pennsylvania | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		952,000
Building and Improvements		9,209,000
Total Real Estate		10,161,000
Accumulated Depreciation		(910,000)
Net Real Estate		9,251,000
Ayr Wellness, Inc. | Nevada | Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs				13,579,000
Ayr Wellness, Inc. | Nevada | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		1,002,000
Building and Improvements		12,577,000
Total Real Estate		13,579,000
Accumulated Depreciation		(297,000)
Net Real Estate		13,282,000
Ayr Wellness, Inc. | Pennsylvania | Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs				14,529,000
Ayr Wellness, Inc. | Pennsylvania | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		2,964,000
Building and Improvements		11,565,000
Total Real Estate		14,529,000
Accumulated Depreciation		(314,000)
Net Real Estate		14,215,000
Bloom Medicinal | Missouri | Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs		350,000		7,301,000
Payments for tenant improvements	$ 5,000,000
Bloom Medicinal | Missouri | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		948,000
Building and Improvements		11,919,000
Total Real Estate		12,867,000
Accumulated Depreciation		(232,000)
Net Real Estate		12,635,000
Calypso Enterprises | Pennsylvania | Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs				30,000,000
Calypso Enterprises | Pennsylvania | Wholly Owned Properties | Mortgage Receivable
Real Estate [Line Items]
Loans receivable							$ 30,000,000
Calypso Enterprises | Pennsylvania | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		1,486,000
Building and Improvements		28,514,000
Total Real Estate		30,000,000
Accumulated Depreciation		(668,000)
Net Real Estate		29,332,000
Columbia Care | California | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		1,082,000
Building and Improvements		2,692,000
Total Real Estate		3,774,000
Accumulated Depreciation		(176,000)
Net Real Estate		3,598,000
Columbia Care | Illinois | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		162,000
Building and Improvements		1,053,000
Total Real Estate		1,215,000
Accumulated Depreciation		(66,000)
Net Real Estate		1,149,000
Columbia Care | Illinois | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		801,000
Building and Improvements		10,560,000
Total Real Estate		11,361,000
Accumulated Depreciation		(673,000)
Net Real Estate		10,688,000
Columbia Care | Massachusetts | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		108,000
Building and Improvements		2,212,000
Total Real Estate		2,320,000
Accumulated Depreciation		(156,000)
Net Real Estate		2,164,000
Columbia Care | Massachusetts | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		1,136,000
Building and Improvements		12,690,000
Total Real Estate		13,826,000
Accumulated Depreciation		(1,079,000)
Net Real Estate		12,747,000
Cresco Labs | Illinois | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		276,000
Building and Improvements		50,456,000
Total Real Estate		50,732,000
Accumulated Depreciation		(4,643,000)
Net Real Estate		46,089,000
Curaleaf | Connecticut | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		184,000
Building and Improvements		2,748,000
Total Real Estate		2,932,000
Accumulated Depreciation		(187,000)
Net Real Estate		2,745,000
Curaleaf | Florida | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		388,000
Building and Improvements		75,595,000
Total Real Estate		75,983,000
Accumulated Depreciation		(4,649,000)
Net Real Estate		71,334,000
Curaleaf | Illinois | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		69,000
Building and Improvements		525,000
Total Real Estate		594,000
Accumulated Depreciation		(37,000)
Net Real Estate		557,000
Curaleaf | Illinois | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		65,000
Building and Improvements		959,000
Total Real Estate		1,024,000
Accumulated Depreciation		(70,000)
Net Real Estate		954,000
Curaleaf | Illinois | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		606,000
Building and Improvements		1,128,000
Total Real Estate		1,734,000
Accumulated Depreciation		(81,000)
Net Real Estate		1,653,000
Curaleaf | Illinois | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		281,000
Building and Improvements		3,072,000
Total Real Estate		3,353,000
Accumulated Depreciation		(214,000)
Net Real Estate		3,139,000
Curaleaf | North Dakota | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		779,000
Building and Improvements		1,395,000
Total Real Estate		2,174,000
Accumulated Depreciation		(102,000)
Net Real Estate		2,072,000
Curaleaf | Ohio | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		574,000
Building and Improvements		2,788,000
Total Real Estate		3,362,000
Accumulated Depreciation		(226,000)
Net Real Estate		3,136,000
Curaleaf | Pennsylvania | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		877,000
Building and Improvements		1,041,000
Total Real Estate		1,918,000
Accumulated Depreciation		(95,000)
Net Real Estate		1,823,000
Curaleaf | Pennsylvania | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		216,000
Building and Improvements		2,011,000
Total Real Estate		2,227,000
Accumulated Depreciation		(140,000)
Net Real Estate		2,087,000
Greenlight | Arkansas | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		238,000
Building and Improvements		1,919,000
Total Real Estate		2,157,000
Accumulated Depreciation		(134,000)
Net Real Estate		2,023,000
Mint | Arizona | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		2,400,000
Building and Improvements		11,293,000
Total Real Estate		13,693,000
Accumulated Depreciation		0
Net Real Estate		13,693,000
Organic Remedies | Missouri | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		204,000
Building and Improvements		20,731,000
Total Real Estate		20,935,000
Accumulated Depreciation		(1,369,000)
Net Real Estate		19,566,000
PharmaCann | Massachusetts | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		411,000
Building and Improvements		1,701,000
Total Real Estate		2,112,000
Accumulated Depreciation		(209,000)
Net Real Estate		1,903,000
PharmaCann | Ohio | Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs				$ 1,550,000
PharmaCann | Ohio | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		281,000
Building and Improvements		1,269,000
Total Real Estate		1,550,000
Accumulated Depreciation		(15,000)
Net Real Estate		1,535,000
PharmaCann | Pennsylvania | Wholly Owned Properties | Dispensary
Real Estate [Line Items]
Land		44,000
Building and Improvements		1,271,000
Total Real Estate		1,315,000
Accumulated Depreciation		(81,000)
Net Real Estate		1,234,000
Revolutionary Clinics | Massachusetts | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		926,000
Building and Improvements		41,934,000
Total Real Estate		42,860,000
Accumulated Depreciation		(2,164,000)
Net Real Estate		40,696,000
Trulieve | Pennsylvania | Wholly Owned Properties | Cultivation
Real Estate [Line Items]
Land		1,061,000
Building and Improvements		43,209,000
Total Real Estate		44,270,000
Accumulated Depreciation		(2,794,000)
Net Real Estate		$ 41,476,000

XML

Real Estate - Tenant Improvements Funded (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Real Estate [Line Items]
Payments for tenant improvements	$ 1,402	$ 3,443	$ 45,245
Unfunded Commitments	17,868		3,120
Option to acquire property			16,500
Arizona | Mint
Real Estate [Line Items]
Payments for tenant improvements	752		7,415
Unfunded Commitments	802		1,554
Missouri | Organic Remedies
Real Estate [Line Items]
Payments for tenant improvements	116		4,745
Unfunded Commitments	166		282
Missouri | Bloom Medicinal
Real Estate [Line Items]
Payments for tenant improvements	534		4,682
Unfunded Commitments	16,150		534
Pennsylvania | Ayr Wellness, Inc.
Real Estate [Line Items]
Payments for tenant improvements	0		0
Unfunded Commitments	$ 750		750
Pennsylvania | Trulieve
Real Estate [Line Items]
Payments for tenant improvements			7,046
Unfunded Commitments			0
Massachusetts | Mint
Real Estate [Line Items]
Payments for tenant improvements			349
Unfunded Commitments			0
Massachusetts | PharmaCann
Real Estate [Line Items]
Payments for tenant improvements			25
Unfunded Commitments			0
Florida | Curaleaf
Real Estate [Line Items]
Payments for tenant improvements			20,983
Unfunded Commitments			$ 0

XML

Real Estate - Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Real Estate [Abstract]
2023 (nine months ending December 31, 2023)	$ 1,489
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$ 21,268	$ 21,765

XML

Leases - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) lease	Dec. 31, 2022 USD ($)	Dec. 31, 2020 lease
Lessor, Lease, Description [Line Items]
Number of leases with purchase option | lease	2		2
Total real estate	$ 399,277	$ 399,474
Number of leases | lease	1
ROU asset	$ 273
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets	Other Assets
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities	Other Liabilities
Weighted-average discount rate	5.65%
Remaining lease term (in years)	3 years 4 months 24 days
Revolutionary Clinics
Lessor, Lease, Description [Line Items]
Number of leases | lease	1
Term of contractual rent for security deposit (in months)	3 months
Security deposit	$ 315
Real Estate Investment, Leased Assets with Option to Purchase
Lessor, Lease, Description [Line Items]
Total real estate	$ 6,300
Minimum
Lessor, Lease, Description [Line Items]
Percentage of rent increase	2.00%
Term of tenant improvement funding (in months)	12 months
Maximum
Lessor, Lease, Description [Line Items]
Percentage of rent increase	3.00%
Term of tenant improvement funding (in months)	18 months

XML

Leases - Future Contractual Minimum Rent (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Leases [Abstract]
2023 (nine months ending December 31, 2023)	$ 36,889
2024	51,211
2025	53,405
2026	54,777
2027	56,186
Thereafter	593,151
Total	$ 845,619

XML

Leases - Tenants in Portfolio that Represents the Largest Percentage of Total Revenue (Details) $ in Thousands	1 Months Ended	3 Months Ended
	Aug. 31, 2022	Mar. 31, 2023 USD ($) lease	Mar. 31, 2022 lease
Curaleaf
Real Estate [Line Items]
Number of Leases		10	11
Percentage of Rental Income		25.00%	26.00%
Cresco Labs
Real Estate [Line Items]
Number of Leases		1	1
Percentage of Rental Income		15.00%	17.00%
Trulieve
Real Estate [Line Items]
Number of Leases		1	1
Percentage of Rental Income		12.00%	14.00%
Columbia Care
Real Estate [Line Items]
Number of Leases		5	5
Percentage of Rental Income		9.00%	11.00%
Revolutionary Clinics
Real Estate [Line Items]
Number of Leases			1
Percentage of Rental Income			14.00%
Security deposit | $		$ 315
Calypso
Real Estate [Line Items]
Number of Leases		1
Percentage of Rental Income		8.00%
Calypso | Mortgage Receivable
Real Estate [Line Items]
Sale lease back term (in years)	20 years

XML

Leases - Operating Lease Maturity (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Leases [Abstract]
2023	$ 59
2024	75
2025	77
2026	52
Total Minimum Lease Payments	263
Less Amount Discounted Using Incremental Borrowing Rate	48
Total Lease Liability	$ 215

XML

Loan Receivable (Details) - USD ($) $ in Thousands	Jun. 10, 2022	Mar. 31, 2023	Dec. 31, 2022
Loans and Leases Receivable Disclosure [Line Items]
Loans receivable		$ 5,000	$ 5,000
Unsecured Loan Receivable | Bloom Medicinal
Loans and Leases Receivable Disclosure [Line Items]
Loans receivable	$ 5,000	$ 5,000
Loan interest rate	10.25%
Loan interest rate increase	102.25%

XML

Financings (Details)	Jul. 29, 2022 USD ($) lender	Jan. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Jan. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	May 06, 2022 USD ($)	Jan. 31, 2022 USD ($)	Dec. 20, 2021 USD ($)
Debt Instrument [Line Items]
Revolving Credit Facility			$ 1,000,000		$ 1,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 90,000,000.0					$ 30,000,000.0
Number of additional lenders | lender	2
Minimum variable rate	4.75%
Revolving Credit Facility			1,000,000
Amount available to be drawn			89,000,000
Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Applicable margin	1.00%
Revolving Credit Facility | Fixed Interest Rate For First Three Years
Debt Instrument [Line Items]
Interest rate	5.65%
Potential Expansion of Borrowing Capacity for Additional Lenders | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 100,000,000
Loans Payable
Debt Instrument [Line Items]
Face amount								$ 3,800,000
Interest rate								4.00%
Annual principal payment				$ 1,000,000			$ 1,800,000
Total long-term debt			1,000,000.0
Unamortized discount			$ 10,200
Loans Payable | Forecast
Debt Instrument [Line Items]
Annual principal payment		$ 1,000,000

XML

Related Party Transactions (Details) - Affiliated Entity - director		3 Months Ended
	Aug. 12, 2021	Mar. 31, 2023
HG Vora
Related Party Transaction [Line Items]
Number of directors	4
Number of consecutive days (in days)		60 days
HG Vora | Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term One
Related Party Transaction [Line Items]
Number of directors		2
Number of consecutive days (in days)		60 days
HG Vora | Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term Two
Related Party Transaction [Line Items]
Number of directors		1
Number of consecutive days (in days)		60 days
HG Vora | Common Stock
Related Party Transaction [Line Items]
Minimum ownership percentage		5.00%
HG Vora | Common Stock | Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term One
Related Party Transaction [Line Items]
Minimum ownership percentage		9.00%
HG Vora | Common Stock | Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term Two
Related Party Transaction [Line Items]
Minimum ownership percentage		5.00%
NLCP Holdings, LLC
Related Party Transaction [Line Items]
Number of directors	3
West Stockholders
Related Party Transaction [Line Items]
Number of directors		1
Number of consecutive days (in days)		60 days
West Stockholders | Common Stock
Related Party Transaction [Line Items]
Minimum ownership percentage		5.00%
Pangea
Related Party Transaction [Line Items]
Number of directors	1
Number of consecutive days (in days)	60 days
Pangea | Common Stock
Related Party Transaction [Line Items]
Minimum ownership percentage	4.00%

XML

Noncontrolling Interests - Noncontrolling Interest Activity (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Noncontrolling Interest [Line Items]
Noncontrolling interest	170.00%	1.80%	170.00%	2.10%
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Noncontrolling Interests %	170.00%	1.80%	170.00%	2.10%
Operating Partnership (OP) | OP Units
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance (in shares)	373,582	453,303
OP Units Converted (in shares)		(61,494)
Ending balance (in shares)	373,582	391,809

XML

Stock Based Compensation - Narrative (Details) - USD ($)		3 Months Ended		29 Months Ended	36 Months Ended
	Aug. 12, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unearned dividend equivalents		$ 225,256	$ 76,609
Amortization of compensation costs		$ 308,000	$ 405,000
The 2021 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized (in shares)		2,275,727
Term of plan (in years)		10 years
Shares available for issuance (in shares)		1,943,936
Number of shares of common stock upon vesting for each RSU (in shares)		1
Number of shares of common stock upon vesting for dividend paid (in shares)		1
Restricted Stock Units (RSUs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grants in period (in shares)		27,630	1,044
Shares outstanding (in shares)		75,419	169,136
Shares nonvested (in shares)		56,885	41,960				29,255	45,018
Shares vested in period (in shares)		0
Shares forfeited (in shares)		0	4,102
Unearned dividend equivalents		$ 60,760	$ 26,854
Amortization of compensation costs		100,000	$ 200,000
Unrecognized compensation cost		$ 700,000
Weighted average amortization period (in years)		1 year 7 months 6 days
Restricted Stock Units (RSUs) | The 2021 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares vested (in shares)		18,534	127,176
Shares nonvested (in shares)		56,885	41,960
Performance Stock Units (PSU)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grants in period (in shares)		55,017	0
Shares nonvested (in shares)		121,858	77,742				66,841	77,742
Performance Stock Units (PSU) | The 2021 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grants in period (in shares)		55,017
Shares outstanding (in shares)		121,858	77,742
Unearned dividend equivalents		$ 164,496	$ 49,755
Amortization of compensation costs		200,000	$ 200,000
Unrecognized compensation cost		$ 1,400,000
Weighted average amortization period (in years)		2 years 1 month 6 days
Forfeitures (in shares)		0	0
Vested (in shares)		0	0
Performance Stock Units (PSU) | The 2021 Equity Incentive Plan | Forecast
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares vested in period (in shares)				18,858	55,017	47,983
Fair value (in dollars per share)				$ 24.15	$ 11.23	$ 24.00
Performance Stock Units (PSU) | The 2021 Equity Incentive Plan | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued (in shares)		0
Performance Stock Units (PSU) | The 2021 Equity Incentive Plan | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued (in shares)		243,716
Nonqualified Stock Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued (in shares)	791,790
Exercise price (in dollars per share)	$ 24.00

XML

Stock Based Compensation - Unvested Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Number of Unvested Shares of RSUs
Number of Unvested Shares, beginning balance (in shares)	29,255	45,018
Granted (in shares)	27,630	1,044
Forfeited (in shares)	0	(4,102)
Number of Unvested Shares, ending balance (in shares)	56,885	41,960
Weighted Average Grant Date Fair Value Per Share
Weighted Average Grant Date Fair Value Per Share, beginning balance (in dollars per share)	$ 22.89	$ 27.49
Granted (in dollars per share)	13.38	27.49
Forfeited (in dollars per share)	0	27.49
Weighted Average Grant Date Fair Value Per Share, ending balance (in dollars per share)	$ 18.27	$ 27.49

XML

Stock Based Compensation - Unvested Performance Stock Activity (Details) - Performance Stock Units (PSU) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Number of Unvested Shares of PSUs
Number of Unvested Shares, beginning balance (in shares)	66,841	77,742
Grants in period (in shares)	55,017	0
Number of Unvested Shares, ending balance (in shares)	121,858	77,742
Weighted Average Grant Date Fair Value Per Share
Weighted Average Grant Date Fair Value Per Share, beginning balance (in dollars per share)	$ 24.04	$ 24.04
Granted (in dollars per share)	11.23	0
Weighted Average Grant Date Fair Value Per Share, ending balance (in dollars per share)	$ 18.26	$ 24.04

XML

Warrants - Narrative (Details) - Warrants Issued in Connection with the Merger - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 17, 2021
Class of Warrant or Right [Line Items]
Purchase price of warrant (in dollars per share)	$ 24.00	$ 24.00	$ 24.00	$ 24.00
Merger with Target
Class of Warrant or Right [Line Items]
Number of warrants to purchase (in shares)					602,392
Purchase price of warrant (in dollars per share)					$ 24.00

XML

Warrants - Warrant Activity (Details) - Warrants Issued in Connection with the Merger - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Number of Warrants
Number of Warrants Exercisable, beginning balance (in shares)	602,392	602,392
Number of Warrants Granted (in shares)	0	0
Number of Warrants Exercised (in shares)	0	0
Number of Warrants Exercisable, ending balance (in shares)	602,392	602,392
Weighted Average Exercise Price
Warrants Exercisable, Weighted Average Exercise Price, beginning (in dollars per share)	$ 24.00	$ 24.00
Warrants Granted, Weighted Average Exercise Price (in dollars per share)	0	0
Warrants Exercised, Weighted Average Exercise Price (in dollars per share)	0	0
Warrants Exercisable, Weighted Average Exercise Price, ending (in dollars per share)	$ 24.00	$ 24.00

XML

Stockholders' Equity - Narrative (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) shares	Dec. 31, 2022 shares	Nov. 07, 2022 USD ($)
Preferred Units [Line Items]
Preferred stock, shares authorized (in shares) | shares	100,000,000		100,000,000
Preferred stock outstanding (in shares) | shares	0		0
Stock repurchase program authorized amount | $				$ 10,000,000
Shares repurchased (in shares) | shares	49,307
Average cost per share (in dollars per share) | $ / shares	$ 12.63
Repurchase of common stock | $	$ 622,000
Remaining availability under the program | $	$ 9,400,000
Conversion ratio	1
Unearned dividend equivalents | $	$ 225,256	$ 76,609
Common Stock
Preferred Units [Line Items]
Shares repurchased (in shares) | shares	49,307
OP Units Converted (in shares) | shares	0	61,494
Restricted Stock Units (RSUs)
Preferred Units [Line Items]
Payment of dividend equivalent | $	$ 8,685	$ 1,436
Unearned dividend equivalents | $	$ 60,760	$ 26,854
Series A Preferred Stock
Preferred Units [Line Items]
Preferred stock outstanding (in shares) | shares	0

XML

Stockholders' Equity - Common Dividends, Dividend Equivalents and Distributions Declared (Details) - $ / shares			3 Months Ended
	Mar. 07, 2023	Mar. 15, 2022	Mar. 31, 2023	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Amount per Share/Unit	$ 0.39	$ 0.33	$ 0.39	$ 0.33

XML

Earnings Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net Income Attributable to Noncontrolling Interests	$ 5,868	$ 5,017
Add: Net Income Attributable to Noncontrolling Interest	102	117
Net Income Attributable to Common Stockholders - Diluted	$ 5,970	$ 5,134
Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic (in shares)	21,423,470	21,382,069
Dilutive Effect of Options and Warrants (in shares)	0	65,099
Weighted Average Shares of Common Stock - Diluted (in shares)	21,797,316	21,931,352
Earnings Per Share - Basic
Net Income Attributable to Common Stockholders, Basic (in dollars per share)	$ 0.27	$ 0.24
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholder, Diluted (in dollars per share)	$ 0.27	$ 0.23
Restricted Stock Units (RSUs)
Denominator:
Dilutive Effect of Unvested Restricted Stock Units (in shares)	264	45,809
OP Units
Denominator:
Dilutive Effect of OP Units (in shares)	373,582	438,375

XML

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Carrying Value
Note Receivable	$ 5,000	$ 5,000
Revolving Credit Facility	1,000	1,000
Seller Financing	990	1,986
Fair Value, Inputs, Level 3
Estimated Fair Value
Note Receivable	4,907	4,952
Fair Value, Inputs, Level 2
Estimated Fair Value
Revolving Credit Facility	905	915
Seller Financing	$ 959	$ 1,942

XML

Commitments and Contingencies (Details) $ in Millions	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Unfunded commitments	$ 17.9

XML

Subsequent Events (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	May 11, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Subsequent Event [Line Items]
Payments for tenant improvements		$ 1,402	$ 3,443	$ 45,245
Cultivation Facility In Arizona | Subsequent Event
Subsequent Event [Line Items]
Payments for tenant improvements	$ 800